CN104684408B - Feed addictive composition - Google Patents
Feed addictive composition Download PDFInfo
- Publication number
- CN104684408B CN104684408B CN201380051433.3A CN201380051433A CN104684408B CN 104684408 B CN104684408 B CN 104684408B CN 201380051433 A CN201380051433 A CN 201380051433A CN 104684408 B CN104684408 B CN 104684408B
- Authority
- CN
- China
- Prior art keywords
- feed
- nrrl
- phytase
- lactobacillus
- bacillus subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 366
- 108010011619 6-Phytase Proteins 0.000 claims abstract description 188
- 229940085127 phytase Drugs 0.000 claims abstract description 170
- 241000894006 Bacteria Species 0.000 claims abstract description 79
- 235000005911 diet Nutrition 0.000 claims abstract description 62
- 230000037213 diet Effects 0.000 claims abstract description 62
- 230000000813 microbial Effects 0.000 claims abstract description 58
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 52
- 208000004232 Enteritis Diseases 0.000 claims abstract description 47
- 230000001338 necrotic Effects 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 42
- 235000019621 digestibility Nutrition 0.000 claims abstract description 36
- 235000015097 nutrients Nutrition 0.000 claims abstract description 36
- 230000001717 pathogenic Effects 0.000 claims abstract description 35
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 32
- 239000011574 phosphorus Substances 0.000 claims abstract description 32
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 26
- 230000001603 reducing Effects 0.000 claims abstract description 26
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims abstract description 19
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 230000036826 Excretion Effects 0.000 claims abstract description 9
- 230000029142 excretion Effects 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 240000008371 Bacillus subtilis Species 0.000 claims description 133
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 132
- 229940075615 Bacillus subtilis Drugs 0.000 claims description 130
- 102000004190 Enzymes Human genes 0.000 claims description 119
- 108090000790 Enzymes Proteins 0.000 claims description 119
- 229940088598 Enzyme Drugs 0.000 claims description 76
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 46
- 241000193468 Clostridium perfringens Species 0.000 claims description 46
- 230000001580 bacterial Effects 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 42
- 239000004615 ingredient Substances 0.000 claims description 40
- 235000002949 phytic acid Nutrition 0.000 claims description 34
- 241000186429 Propionibacterium Species 0.000 claims description 33
- 229950002499 Fytic acid Drugs 0.000 claims description 31
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 31
- 229940068041 Phytic Acid Drugs 0.000 claims description 31
- 239000000467 phytic acid Substances 0.000 claims description 31
- 241000588724 Escherichia coli Species 0.000 claims description 30
- 241000186660 Lactobacillus Species 0.000 claims description 27
- 241000194108 Bacillus licheniformis Species 0.000 claims description 26
- 229940039696 Lactobacillus Drugs 0.000 claims description 24
- 240000001929 Lactobacillus brevis Species 0.000 claims description 23
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 23
- 229920000406 phosphotungstic acid polymer Polymers 0.000 claims description 21
- 210000000936 Intestines Anatomy 0.000 claims description 20
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 19
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 19
- 229940039695 Lactobacillus acidophilus Drugs 0.000 claims description 19
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 19
- 230000002223 anti-pathogen Effects 0.000 claims description 19
- 229960000367 Inositol Drugs 0.000 claims description 18
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 18
- 241000194031 Enterococcus faecium Species 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 241000186000 Bifidobacterium Species 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- 229930003231 vitamins Natural products 0.000 claims description 15
- 241000186425 Acidipropionibacterium jensenii Species 0.000 claims description 14
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 244000057717 Streptococcus lactis Species 0.000 claims description 14
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 14
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
- 235000010755 mineral Nutrition 0.000 claims description 13
- 239000011707 mineral Substances 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 241000186841 Lactobacillus farciminis Species 0.000 claims description 12
- 229940088594 Vitamin Drugs 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- 210000000481 Breast Anatomy 0.000 claims description 11
- 240000000218 Cannabis sativa Species 0.000 claims description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 11
- LWGJTAZLEJHCPA-UHFFFAOYSA-N N-(2-chloroethyl)-N-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241001622847 Buttiauxella Species 0.000 claims description 10
- 240000004403 Lactobacillus casei Species 0.000 claims description 10
- 229940017800 Lactobacillus casei Drugs 0.000 claims description 10
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 10
- 241000607142 Salmonella Species 0.000 claims description 10
- 241000726221 Gemma Species 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 9
- 241000228212 Aspergillus Species 0.000 claims description 8
- 241000194033 Enterococcus Species 0.000 claims description 8
- 241000194036 Lactococcus Species 0.000 claims description 8
- 241000192001 Pediococcus Species 0.000 claims description 8
- 101710007878 RPS15 Proteins 0.000 claims description 8
- 241000589876 Campylobacter Species 0.000 claims description 7
- 241000588923 Citrobacter Species 0.000 claims description 7
- 210000003608 Feces Anatomy 0.000 claims description 7
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 6
- 229940001882 Lactobacillus reuteri Drugs 0.000 claims description 6
- 244000052616 bacterial pathogens Species 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 5
- 240000006439 Aspergillus oryzae Species 0.000 claims description 5
- 241000588731 Hafnia Species 0.000 claims description 5
- 241000228143 Penicillium Species 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 claims description 5
- 241001478240 Coccus Species 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 4
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims description 4
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 claims description 4
- 241000223259 Trichoderma Species 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- 108010080981 3-phytase Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 241000123255 Peniophora Species 0.000 claims 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N Rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 claims 2
- 210000003296 Saliva Anatomy 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 17
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 67
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 47
- 239000000047 product Substances 0.000 description 37
- 239000000843 powder Substances 0.000 description 31
- 240000008042 Zea mays Species 0.000 description 28
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 28
- 239000002245 particle Substances 0.000 description 28
- 238000011160 research Methods 0.000 description 26
- 239000011248 coating agent Substances 0.000 description 23
- 238000000576 coating method Methods 0.000 description 23
- 235000005822 corn Nutrition 0.000 description 22
- 235000005824 corn Nutrition 0.000 description 22
- 235000013305 food Nutrition 0.000 description 20
- 230000000529 probiotic Effects 0.000 description 19
- 239000006041 probiotic Substances 0.000 description 19
- 235000018291 probiotics Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 235000013339 cereals Nutrition 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 239000000969 carrier Substances 0.000 description 17
- 235000019688 fish Nutrition 0.000 description 17
- 244000005700 microbiome Species 0.000 description 17
- 240000008529 Triticum aestivum Species 0.000 description 16
- 235000015165 citric acid Nutrition 0.000 description 16
- 244000052769 pathogens Species 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 235000021307 wheat Nutrition 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 15
- 229940032147 Starch Drugs 0.000 description 15
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000002829 reduced Effects 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- 235000010469 Glycine max Nutrition 0.000 description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 238000006722 reduction reaction Methods 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 241000251468 Actinopterygii Species 0.000 description 13
- 229940023488 Pill Drugs 0.000 description 13
- 239000006187 pill Substances 0.000 description 13
- 241000193163 Clostridioides difficile Species 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000004459 forage Substances 0.000 description 12
- 244000144977 poultry Species 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 241000193403 Clostridium Species 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 11
- 210000002303 Tibia Anatomy 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 11
- 210000004215 spores Anatomy 0.000 description 11
- -1 Bacitracin Zinc Chemical compound 0.000 description 10
- 230000001976 improved Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229960005069 Calcium Drugs 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 235000019738 Limestone Nutrition 0.000 description 9
- 239000005913 Maltodextrin Substances 0.000 description 9
- 229920002774 Maltodextrin Polymers 0.000 description 9
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 9
- 229960004793 Sucrose Drugs 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 239000006028 limestone Substances 0.000 description 9
- 229940035034 maltodextrin Drugs 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 8
- 229960001375 Lactose Drugs 0.000 description 8
- 206010039447 Salmonellosis Diseases 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 239000002054 inoculum Substances 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 230000002503 metabolic Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 229960003563 Calcium Carbonate Drugs 0.000 description 7
- 235000019746 Digestible methionine Nutrition 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 240000007842 Glycine max Species 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000000996 additive Effects 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000013372 meat Nutrition 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 235000013619 trace mineral Nutrition 0.000 description 7
- 210000003405 Ileum Anatomy 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 6
- 240000005158 Phaseolus vulgaris Species 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 6
- 230000003115 biocidal Effects 0.000 description 6
- 235000012970 cakes Nutrition 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000002255 enzymatic Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000009973 maize Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Polymers 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 244000075850 Avena orientalis Species 0.000 description 5
- 235000007319 Avena orientalis Nutrition 0.000 description 5
- 235000007558 Avena sp Nutrition 0.000 description 5
- 241000194103 Bacillus pumilus Species 0.000 description 5
- 235000019750 Crude protein Nutrition 0.000 description 5
- 206010022114 Injury Diseases 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 240000006394 Sorghum bicolor Species 0.000 description 5
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 230000001332 colony forming Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 235000006109 methionine Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- 235000019745 Digestible lysine Nutrition 0.000 description 4
- 235000019748 Digestible threonine Nutrition 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 235000019765 Maize DDGS Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 4
- 235000007238 Secale cereale Nutrition 0.000 description 4
- 240000002057 Secale cereale Species 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 230000003213 activating Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000011436 cob Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000010903 husk Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000007427 paired t-test Methods 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000001502 supplementation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 229960005486 vaccines Drugs 0.000 description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 3
- BLGYKMPTFOIOCW-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;propanedioic acid Chemical compound OC(=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O BLGYKMPTFOIOCW-UHFFFAOYSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 235000006008 Brassica napus var napus Nutrition 0.000 description 3
- 240000000385 Brassica napus var. napus Species 0.000 description 3
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 3
- 240000002268 Citrus limon Species 0.000 description 3
- 208000003495 Coccidiosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N DL-methionine Chemical class CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- 241000223934 Eimeria maxima Species 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 210000004317 Gizzard Anatomy 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 229940029339 Inulin Drugs 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 229940072205 Lactobacillus plantarum Drugs 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 3
- 240000003705 Senecio vulgaris Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 240000001016 Solanum tuberosum Species 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- 229940029983 VITAMINS Drugs 0.000 description 3
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 235000019728 animal nutrition Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 235000008984 brauner Senf Nutrition 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 150000003045 fructo oligosaccharides Chemical class 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- 206010000496 Acne Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940004120 Bifidobacterium Infantis Drugs 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 229940118852 Bifidobacterium animalis Drugs 0.000 description 2
- 241001134770 Bifidobacterium animalis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 229940002008 Bifidobacterium bifidum Drugs 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 241001622848 Buttiauxella agrestis Species 0.000 description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N Carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 2
- 241000588919 Citrobacter freundii Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 240000007170 Cocos nucifera Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 241000223924 Eimeria Species 0.000 description 2
- 239000004258 Ethoxyquin Substances 0.000 description 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N Ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 2
- 229940093500 Ethoxyquin Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 235000019733 Fish meal Nutrition 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 240000006962 Gossypium hirsutum Species 0.000 description 2
- 235000019754 Grower Diet Nutrition 0.000 description 2
- 240000006669 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241000186679 Lactobacillus buchneri Species 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 229940004208 Lactobacillus bulgaricus Drugs 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241001134659 Lactobacillus curvatus Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 229940054346 Lactobacillus helveticus Drugs 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001561398 Lactobacillus jensenii Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 235000019735 Meat-and-bone meal Nutrition 0.000 description 2
- 241000604449 Megasphaera Species 0.000 description 2
- 230000036091 Metabolic activity Effects 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N Sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 235000019285 ethoxyquin Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000004467 fishmeal Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000887 hydrating Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000004001 inositols Chemical class 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000004550 soluble concentrate Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000015099 wheat brans Nutrition 0.000 description 2
- LKDRXBCSQODPBY-DPYQTVNSSA-N β-D-tagatopyranose Chemical compound OC[C@@]1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-DPYQTVNSSA-N 0.000 description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2S,3R,4S,5S,6R)-2-[(2R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- PBWPWIZUYLTJNF-UHFFFAOYSA-N 2-aminoacetic acid;calcium Chemical compound [Ca].NCC(O)=O PBWPWIZUYLTJNF-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- NYNKCGWJPNZJMI-UHFFFAOYSA-N 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide;2-hydroxybutanedioic acid Chemical compound [O-]C(=O)C(O)CC(O)=O.COC1=CC(N)=C(Cl)C=C1C(=O)NC1CC[NH+](CC=2C=CC=CC=2)CC1 NYNKCGWJPNZJMI-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-IPFGBZKGSA-N 6-O-α-D-glucopyranosyl-β-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@](O)(CO)O1 PVXPPJIGRGXGCY-IPFGBZKGSA-N 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N ALLICIN Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 241000186426 Acidipropionibacterium acidipropionici Species 0.000 description 1
- 241000186335 Acidipropionibacterium thoenii Species 0.000 description 1
- 241001088417 Ammodytes americanus Species 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 235000019758 Animal/vegetable fat blend Nutrition 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000004190 Avilamycin Substances 0.000 description 1
- 239000004184 Avoparcin Substances 0.000 description 1
- JWFVWARSGMYXRN-HTQQBIQNSA-N Avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 1
- 229950001335 Avoparcin Drugs 0.000 description 1
- 229940075612 Bacillus cereus Drugs 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Chemical class CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 229940009289 Bifidobacterium lactis Drugs 0.000 description 1
- 229940009291 Bifidobacterium longum Drugs 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 241000726108 Blastocystis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940105657 CATALASE Drugs 0.000 description 1
- 229940041514 Candida albicans extract Drugs 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 241000206594 Carnobacterium Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 1
- 229960003178 Choline Chloride Drugs 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M Choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N Cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 241001494522 Citrobacter amalonaticus Species 0.000 description 1
- 241000580513 Citrobacter braakii Species 0.000 description 1
- 241000949040 Citrobacter gillenii Species 0.000 description 1
- 241000936506 Citrobacter intermedius Species 0.000 description 1
- 229940092534 Citrobacter koseri Drugs 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 241000949041 Citrobacter murliniae Species 0.000 description 1
- 241000949031 Citrobacter rodentium Species 0.000 description 1
- 241000949032 Citrobacter sedlakii Species 0.000 description 1
- 241000949039 Citrobacter werkmanii Species 0.000 description 1
- 241000920610 Citrobacter youngae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229940038704 Clostridium perfringens Drugs 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-levulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 1
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229940096118 Ella Drugs 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000321429 Epinephelus itajara Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 210000003746 Feathers Anatomy 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 241000276435 Gadus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000588729 Hafnia alvei Species 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 229940068140 Lactobacillus bifidus Drugs 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 210000003750 Lower Gastrointestinal Tract Anatomy 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 102100011518 NT5C3A Human genes 0.000 description 1
- 101710017472 NT5C3A Proteins 0.000 description 1
- 240000008059 Nerium oleander Species 0.000 description 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 240000008114 Panicum miliaceum Species 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 235000002098 Puffbohne Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000003660 Reticulum Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N Ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229940005581 Sodium Lactate Drugs 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 description 1
- 229940075554 Sorbate Drugs 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 229940063650 Terramycin Drugs 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N Thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 241000713154 Toscana virus Species 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 229940120293 Vaginal Suppository Drugs 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 229960003842 Virginiamycin Drugs 0.000 description 1
- FEPMHVLSLDOMQC-UHFFFAOYSA-N Virginiamycin Chemical compound CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O FEPMHVLSLDOMQC-UHFFFAOYSA-N 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 235000019752 Wheat Middilings Nutrition 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2R,3S,4R,6S)-6-[(2'R,3'S,3aR,4R,4'R,6S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(2R,3aS,3'aR,6'R,7R,7'S,7aR,7'aR)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3aH- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (E)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- JCCZVLHHCNQSNM-UHFFFAOYSA-N [Na][Si] Chemical compound [Na][Si] JCCZVLHHCNQSNM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000433 anti-nutritional Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000019379 avilamycin Nutrition 0.000 description 1
- 229960005185 avilamycin Drugs 0.000 description 1
- 235000019377 avoparcin Nutrition 0.000 description 1
- 108010053278 avoparcin Proteins 0.000 description 1
- 229960005364 bacitracin zinc Drugs 0.000 description 1
- 210000004666 bacterial spores Anatomy 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 229950007118 bambermycin Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 235000006442 blackseeded proso millet Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000006443 broomcorn panic Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000006419 common millet Nutrition 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000019620 fat digestibility Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019374 flavomycin Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010908 plant waste Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 229910001388 sodium aluminate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229930007823 thymol Natural products 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229960000200 ulipristal Drugs 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Performance for improving individual,Or digestibility (such as the Nutrient digestibility for improving the raw material in feed,Such as amino acid digestibility),Or retain for improving nitrogen,Or for improving the absorption of diet phosphorus and retaining,Or the effect of for improving phytase,Or the resistance for improving individual to necrotic enteritis,Or for improving feed conversion rate (FCR),Or for improving the weightening in individual,Or for improving the feed efficiency in individual,Or the immune response for adjusting (such as improvement) individual,Or the population of the pathogenic bacteria in the gastrointestinal tract for reducing individual,Or the method for reducing the excretion of the nutrients in muck,This method includes the combination to individual application at least one Direct-Fed Microbials and phytase,The dosage wherein pressed more than about 1500FTU/kg feeds applies the phytase to the individual.
Description
Technical field
The present invention relates to the groups at least one Direct-Fed Microbials and one or more high dose phytases
Closing improves the method for fodder compound, and includes at least one Direct-Fed Microbials and one or more high dose inositols six
The feed addictive composition of the combination of phosphatase.The invention further relates to purposes and kit.
Background technology
Necrotic enteritis is disease economically important in poultry species.It is because of pathogen C.perfringens
(Clostridium perfringens) is infected and is generated, often with coccidiosis infection.In extreme circumstances, it leads to Gao Shui
The flat death rate, and the adverse effect for leading to damage of intestines in subclinical levels and animal being showed.Mainly pass through feeding antibiotic
Use control necrotic enteritis and its negative effect.But feeding antibiotic is used as the ban of growth promoter and is disappeared
Expense person makes the producer be more difficult to prevent by C.perfringens the pressure used for reducing the antibiotic applied to meat producing animal
And loss caused by relevant subclinical or clinical necrotic enteritis.Accordingly, there exist provide limitation or prevent by perfringens shuttle
The chance of the solution of microbial damage.One this solution is with probiotics come the micro- life of sanatory enteron aisle
Object fauna and the enterology ecosystem stablized.But just other are observed with the enzyme supplement of such as protease and carbohydrase
Benefit.Although having contemplated that the combination of DFM and some enzymes, always without understanding the interaction between DFM and enzyme completely.This hair
It is bright to be related to new specific combination, astoundingly significantly improve the production performance characteristic of animal.
Known nonruminant does not include endogenous phytase in stomach and small intestine or comprising the insignificant endogenous flesh of amount
Alcohol six-phosphatase, therefore come in the alimentary canal of proximal end dependent on the plant and/or microorganism supplemented or fungi phytase
Six phosphoric acid of hydrolysis of inositol (Pallauf, J. and Rimbach, G.Arch.Anim.Nutr., volume 1997,50,301-319 pages).It is logical
Additional phytase is often added to the feed of nonruminant (such as poultry and pannage).Phytase be cereal and
The major storage form of phosphorus in beans.By the effect of phytase, phytic acid, which usually hydrolyzes, generates rudimentary inositol
Phosphoric acid and inorganic phosphate.
The present invention, which seeks to overcome, to be reduced with phytase in the animal with clinical or subclinical necrotic enteritis
Beneficial effect correlation problem in some.
The present invention also seeks to overcome with phytic acid especially in the animal with clinical or subclinical necrotic enteritis
In anti-nutritive properties correlation problem, lead to the validity for improving nutrients, minerals, vitamin and energy, and therefore change
The biophysics feature of kind nonruminant.
Summary of the invention
The present invention initiative be the discovery that, the inventors discovered that, at least one DFM with high level (>1500FTU/kg is raised
Material) phytase combination in there are synergistic effect beyong contemplation, have been displayed its by individual performance improve it is supreme
In the horizontal level of the positive control with low-level C.perfringens and without necrotic enteritis.
The present inventor is by considering that such as Percentage mortality, weight gain and FCR demonstrate this discovery.These fronts
Effect is entirely unexpected.
It is not intended to be limited to theory, inventors believe that, these effects can be by (such as being produced by pathogen compared with the control
Gas capsular clostridium and/or Escherichia coli (Escherichia coli) attack) caused by the reduction of damage of intestines level cause.
The improvement of animal performance can be by preventing harmful bacteria colonizing in enteron aisle from being explained with pathology.In addition,
Think that other beneficial effects of the present invention include that the hydrolysis of phytic acid increases, the ileum of protein and minerals is caused to disappear
Rate improves.In addition to the benefit of the raising nutrients validity of individual, this may further result in less substrate and reaches hindgut use
In bacterial fermentation so that the pathogen in enteron aisle is more difficult to colonize.The present invention's another benefit is that, and do not supplement phytic acid
It is compared when enzyme, the generation of mucin is reduced.Accordingly, there exist the forfeitures of the endogenous of reduced levels, and same less substrate is used for
Intestinal microflora is fermented.
Specifically, the present invention initiative be the discovery that at least one Direct-Fed Microbials (DFM) with high level (>
1500FTU/kg feeds) the combination of phytase there is significant beneficial effect to the performance of animal, including improve with
It is one or more in lower:Feed conversion rate (FCR), ability (such as Nutrient digestibility, such as amino acid digestion for digesting raw material
Rate), nitrogen reservation, survival rate, dressing percentage, growth rate, weightening, feed efficiency, animal is to the resistance of necrotic enteritis, individual
Immune response.
Another surprising effect of the present invention is that it can reduce the excretion of the nutrients in muck (manure) and (such as subtract
Nitrogen and phosphorus content in the muck of few individual).
In another aspect of this invention, such method, this method are provided:
I) it is used to improve the performance of individual;Or
Ii) it is used to improve the digestibility (such as Nutrient digestibility, such as amino acid digestibility) of the raw material in feed;Or
Iii it) is used to improve phosphorus (such as diet phosphorus) to absorb and retain;Or
Iv the effect of) being used to improve phytase;Or
V) it is used to improve nitrogen reservation;Or
Vi the resistance for) being used to improve individual to necrotic enteritis;Or
Vii it) is used to improve feed conversion rate (FCR);Or
Viii it) is used to improve the weightening in individual;Or
Ix it) is used to improve the feed efficiency in individual;Or
X) it is used to adjust the immune response of (such as improvement) individual;Or
Xi) it is used to reduce the population of the pathogenic bacteria in individual gastrointestinal tract;Or
Xii the nutrients excretion in muck) is reduced;
This method includes the combination to individual application at least one Direct-Fed Microbials and phytase, wherein pressing
Dosage more than about 1500FTU/kg feeds applies the phytase to the individual.
Another aspect of the present invention is the purposes of the combination of at least one Direct-Fed Microbials and phytase,
In by more than about 1500FTU/kg feeds dosage use the phytase:
I) it is used to improve the performance of individual;Or
Ii) it is used to improve the digestibility (such as Nutrient digestibility, such as amino acid digestibility) of the raw material in feed;Or
Iii it) is used to improve nitrogen reservation;Or
Iv it) is used to improve phosphorus (such as diet phosphorus) to absorb and retain;Or
V) the effect of being used to improve phytase;Or
Vi the resistance for) being used to improve individual to necrotic enteritis;Or
Vii it) is used to improve feed conversion rate (FCR);Or
Viii it) is used to improve the weightening in individual;Or
Ix it) is used to improve the feed efficiency in individual;Or
X) it is used to adjust the immune response of (such as improvement) individual;Or
Xi) it is used to reduce the population of the pathogenic bacteria in individual gastrointestinal tract;Or
Xii the nutrients excretion in muck) is reduced.
The present invention also provides include at least one Direct-Fed Microbials and the addition of the feed of the combination of phytase
Agent composition, the wherein phytase are by existing below in the feed addictive composition:
A. when being added in feed by least 50g/ tonnes of (MT) feed, by about 30,000FTU/g compositions or more;
B. when being added in feed by least 75g/ tonnes of (MT) feed, by about 20,000FTU/g compositions or more;
C. when being added in feed by least 100g/ tonnes of (MT) feed, by about 15,000FTU/g compositions or more;
D. when being added in feed by least 100g/ tonnes of (MT) feed, by about 15,000FTU/g compositions or more;
E. when being added in feed by least 150g/ tonnes of (MT) feed, by about 10,000FTU/g compositions or more;
F. when being added in feed by least 200g/ tonnes of (MT) feed, by about 7,500FTU/g compositions or more;
G. when being added in feed by least 300g/ tonnes of (MT) feed, by about 5,000FTU/g compositions or more;
And wherein the Direct-Fed Microbials are pressed from 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:The model of 1FTU enzymes
It encloses and is present in the feed addictive composition.
In another aspect of this invention, the reagent of feed addictive composition and operation instructions comprising the present invention is provided
Box.
In another aspect of this invention, the method for preparing feed addictive composition is provided comprising will be at least one straight
It connects feeding microorganism to combine with phytase so that the dosage of the composition mysoinositol six-phosphatase:
A. it is about 30,000FTU/g compositions or more when being added in feed by least 50g/ tonnes of (MT) feed;
B. it is about 20,000FTU/g compositions or more when being added in feed by least 75g/ tonnes of (MT) feed;
C. it is about 15,000FTU/g compositions or more when being added in feed by least 100g/ tonnes of (MT) feed;
D. it is about 15,000FTU/g compositions or more when being added in feed by least 100g/ tonnes of (MT) feed;
E. it is about 10,000FTU/g compositions or more when being added in feed by least 150g/ tonnes of (MT) feed;
F. it is about 7,500FTU/g compositions or more when being added in feed by least 200g/ tonnes of (MT) feed;
G. it is about 5,000FTU/g compositions or more when being added in feed by least 300g/ tonnes of (MT) feed;
And in the feed addictive composition Direct-Fed Microbials dosage from 2.5x103CFUDFM:1FTU enzymes
To 6.7x106CFU:In the range of 1FTU enzymes, and (optionally) packaging.
In another aspect of this invention, the feed of the feed addictive composition comprising the present invention is provided.
The present invention furthermore provides the method for preparing feed (feedstuff) comprising by feed ingredient and the present invention
Feed addictive composition mixing.
On the other hand, the present invention is provided comprising feed addictive composition and at least one minerals and/or at least one
The pre-composition of kind of vitamin, the feed addictive composition contain at least one Direct-Fed Microbials and phytase
Combination, the wherein phytase are by existing below in the pre-composition:
A. when being added in feed by least 50g/ tonnes of (MT) feed, by about 30,000FTU/g compositions or more;
B. when being added in feed by least 75g/ tonnes of (MT) feed, by about 20,000FTU/g compositions or more;
C. when being added in feed by least 100g/ tonnes of (MT) feed, by about 15,000FTU/g compositions or more;
D. when being added in feed by least 100g/ tonnes of (MT) feed, by about 15,000FTU/g compositions or more;
E. when being added in feed by least 150g/ tonnes of (MT) feed, by about 10,000FTU/g compositions or more;
F. when being added in feed by least 200g/ tonnes of (MT) feed, by about 7,500FTU/g compositions or more;
G. when being added in feed by least 300g/ tonnes of (MT) feed, by about 5,000FTU/g compositions or more;
And the Direct-Fed Microbials are pressed from 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:The range of 1FTU enzymes is deposited
It is in the pre-composition.
The present invention also provides the present invention feed addictive composition or the present invention pre-composition or include the present invention feeding
The feed of feed additives composition (or pre-composition), for preventing and/or treating globidiosis and/or gangrenosum acne intestines in individual
It is scorching.
In a still further aspect thereof, the method that prevention is provided and/or treats necrotic enteritis and/or globidiosis,
In to the feed addictive composition of a effective amount of present invention of individual application or the pre-composition of the present invention or include of the invention feeding
The feed of feed additives composition (or pre-composition).
In the broad aspect of the present invention, method or purposes are furthermore provided:
I) it is used to improve the digestibility (such as Nutrient digestibility, such as amino acid digestibility) of the raw material in feed;Or
Ii) it is used to improve the performance of individual;Or
Iii it) is used to improve phosphorus (such as diet phosphorus) to absorb and retain;Or
Iv the effect of) being used to improve phytase;Or
V) it is used to improve nitrogen reservation;Or
Vi the resistance for) being used to improve individual to necrotic enteritis;Or
Vii it) is used to improve feed conversion rate (FCR);Or
Viii it) is used to improve the weightening in individual;Or
Ix it) is used to improve the feed efficiency in individual;Or
X) it is used to adjust the immune response of (such as improvement) individual;Or
Xi) it is used to reduce the population of the pathogenic bacteria in individual gastrointestinal tract;Or
Xii the nutrients excretion in muck) is reduced;
This method includes to individual administered with high dose phosphoric acid, together with the compound for reducing the pH in individual gastrointestinal tract (GIT).
In this broad aspect, which can be suitably organic acid, essential oil or antibiotic.The organic acid can be selected from citric acid, prolong
Fumarate, formic acid, propionic acid, lactic acid and benzoic acid.It is mould that the antibiotic can be selected from tetracycline, duomycin, terramycin, oleander
Element, spiramvcin, Virginiamycin, Bacitracin Zinc, moenomycin (bambermycin), avilamycin and avoparcin.The essential oil (or plant extracts)
Cinnemaldehyde, thymol, carvacrol, capsaicine, Eugenol (euganol) and alicin can be selected from.
Brief description
Fig. 1 displays supplement EnvivaPro and high phytic acid enzyme dosage (3000FTU/kg) in necrotic enteritis to attacking
Hit the influence of the weight gain of broiler chicken (broiler) of the lower raising to 42 days.
Fig. 2 displays supplement EnvivaPro and high phytic acid enzyme dosage (3000FTU/kg) in necrotic enteritis to attacking
Hit the influence of the FCR of broiler chicken of the lower raising to 42 days.
Fig. 3 shows that EnvivaPro and high phytic acid enzyme dosage (3000FTU/kg) cause necrotic enteritis attack
The death rate influence.
Fig. 4 shows that EnvivaPro and high phytic acid enzyme dosage (3000FTU/kg) cause necrotic enteritis attack
Damage of intestines severity influence.
Fig. 5 is shown under necrotic enteritis attack, in the case where existing and lacking Enviva Pro, the flesh of various dose
The influence of FCR of the alcohol six-phosphatase to broiler chicken from the 0th day to the 21st day.
Fig. 6 shows the influence of FCR of the phytase of various dose to broiler chicken from the 6th day to the 35th day.
Fig. 7 is shown under necrotic enteritis attack, with and without Enviva Pro, various dose
HiPhosTMThe influence of FCR of the phytase to broiler chicken from the 0th day to the 21st day.
Fig. 8 is shown under necrotic enteritis attack, with and without Enviva Pro, different level
HiPhosTMPhytase to broiler chicken the 21st day shin bone (tibia) bone ash influence.
Detailed description of the invention
Preferably, it is exogenous for DFM for each in the enzyme of the present invention.In other words, preferably by enzyme
It is added in DFM or is mixed with DFM.
Unless otherwise defined, all technical and scientific terms used herein all have disclosure fields common
The normally understood meaning of technical staff.Singleton, etc. DICTIONARY OF MICROBIOLOGY AND MOLECULAR
BIOLOGY, the 20th edition, John Wiley and Sons, New York (1994) and Hale&Marham, THE HARPER
COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide for those skilled in the art
The general dictionary of many terms used in the disclosure.
The disclosure is not limited to illustrative methods disclosed herein and material, it is any with those described herein method and
The similar or equivalent method of material and material can be used in the implementation or test of the embodiment of the disclosure.Numberical range includes limit
The number of the fixed range.Unless otherwise specified, being respectively, any nucleic acid sequence is write out with 5' to the directions 3' from left to right;
Amino acid sequence is write out with amino to carboxyl direction from left to right.
Title provided herein is not these aspects or implementation to a variety of aspects of the disclosure or the limitation of embodiment
Scheme can be obtained by considering the specification as a whole to refer to.Correspondingly, the term that will hereafter define will be by that will say
Bright book refers to as a whole to be obtained more completely defining.
Amino acid is referred to amino acid name, trigram abbreviation or one-letter abbreviations herein.
The term as used herein " protein " includes protein, polypeptide and peptide.
The term as used herein " amino acid sequence " is synonymous with term " polypeptide " and/or term " protein ".In some feelings
Under condition, term " amino acid sequence " is synonymous with term " peptide ".In some cases, term " amino acid sequence " and term " enzyme " are same
Justice.
Term " protein " and " polypeptide " are used interchangeably herein.In the disclosure and claims, it can be used
A conventional letter and three-letter codes for amino acid residue.3 alphanumeric codes of amino acid are in accordance with IUPACIUB biological chemical names
The definition of joint committee (Joint Commission on Biochemical Nomenclature, JCBN).It should also be understood that
Due to the degeneracy of genetic code, polypeptide can be nucleotide sequence coded by more than one.
Other definition of term can occur in entire this specification.Be more fully described exemplary implementation scheme it
Before, it should be understood that the disclosure is not limited to described specific embodiment, because what these embodiments certainly can be changed.Also answer
Understand, the term as used herein merely for description specific embodiment purpose, be not intended to it is in a limiting sense, because of this hair
Bright range will be only limited by the following claims.
When providing numberical range, it should be appreciated that unless the context clearly dictates otherwise, also clearly disclose the range the upper limit and
Each intermediate value between lower limit (to 1/10th of a position (unit) of lower limit).Arbitrary described value in the range or
Each smaller range between other arbitrary described values or median in median and the range is also covered by the disclosure.
These small range of upper and lower bounds can be independently include within the scope of this or exclude outside the range, and any of which,
Neither one or two boundaries are included in each range in smaller range and are also covered by the disclosure, according in the range
Depending on the arbitrary boundary clearly excluded.In the case where the range includes one or two of boundary, excludes these and wrapped
The range of either one or two of the boundary included is also included in the disclosure.
It must be noted that unless the context clearly dictates otherwise, herein with singulative used in appended claims " one ",
"one" and "the" include plural object.Thus, for example, it includes multiple this candidate substances to mention " enzyme " then, and mentions and " raising
Material " includes then mentioning one or more feeds and their equivalent well known by persons skilled in the art, and so on.
The publication being discussed herein is intended merely to their disclosures before the submitting day of the application and provides.Herein
Any content be all not interpreted as recognizing the prior art that these publications constitute this paper appended claims.
Enzyme for the present invention can be generated by solid culture or deep drainpipe, including batch processes, fed-batch side
Method and continuous flow method.Culture complete in the medium, the culture medium include aqueous mineral salt culture medium, organic growth factors,
Carbon and energy substance, the molecular oxygen and initial inoculation for also having one or more specific microbial species ready for use certainly
Object.
Direct-Fed Microbials (DFM) for the present invention can be antipathogen Direct-Fed Microbials.It is used herein
Term " antipathogen DFM " mean to inhibit (such as reduce or prevent) pathogenic microorganisms (such as C.perfringens and/or large intestine
Bacillus and/or Salmonella ssp (Salmonella spp.) and/or campylobacter species (Campylobacter
Spp.), preferably C.perfringens and/or Escherichia coli) the DFM that colonizes of enteral.
" the DFM measurement " hereafter instructed may be used to determine whether DFM is antipathogen DFM.
In one embodiment, inhibition bacterial strain (or disease-resistant original when selection " DFM measurement " assessment instructed herein
Body DFM) as the DFM for the present invention.
Expediently, the DFM for the present invention can inhibit the one (or more) kinds in following pathogen:Clostridial species
(Clostridium spp), such as C.perfringens and/or clostridium difficile (Clostridium difficile), and/or it is big
Enterobacteria and/or Salmonella ssp and/or campylobacter species, at least one of preferably following pathogen (or it is more
Kind):Clostridial species, such as C.perfringens and/or clostridium difficile and/or Escherichia coli.
In one embodiment, the DFM for the present invention can inhibit the one (or more) kinds in following pathogen:Production
Gas capsular clostridium and/or clostridium difficile and/or Escherichia coli, preferably C.perfringens and/or clostridium difficile, more preferable aerogenesis
Capsular clostridium.
In one embodiment, individual can be one or more in such as following pathogen by following pathogen challenge:Clostridium
Species, such as C.perfringens and/or clostridium difficile and/or Escherichia coli and/or Salmonella ssp and/or bending
Bacillus species.
In one embodiment, individual can be attacked by C.perfringens and/or Escherichia coli.
DFM for the present invention is suitably bacterium living.
The present invention relates to high phytic acid enzyme dosages.
In general, giving phytase for example for broiler chicken and turkey by the range of about 500FTU/kg feeds, usually press
The range of about 300FTU/kg feeds, which is given, is used for such as laying hen.
On the contrary, in the present invention, by least 1500FTU/kg feeds, suitably at least 2000FTU/kg feeds, suitably
At least 3000FTU/kg feeds, suitably at least 5000FTU/kg feeds, such as 10000FTU/kg feeds it is horizontal by six phosphorus of inositol
Sour enzyme is added in feed (or being added together with feed).
As will be understood by those skilled, the level of the phytase in feed addictive composition must be enough
Allow by least 1500FTU/kg feeds, suitably at least 2000FTU/kg feeds, suitably at least 3000FTU/kg feeds, suitable
Preferably at least phytase is added in feed by 5000FTU/kg feeds, the horizontal of such as 10000FTU/kg feeds.
It has been found by the present inventors that significant benefit can be obtained by the way that high phytic acid enzyme level is administered in combination with DFM.
On the contrary, the dosage for individually increasing phytase does not generate notable benefit (for example, the nothing such as feed conversion rate significantly improves).Shape
At striking contrast, increase phytase being combined at least one DFM (especially at least a kind of antipathogen DFM)
When dosage, then notable and unexpected benefit is observed.This is entirely unexpected.
Expediently, the DFM for the present invention is the mixture of at least two DFM, suitably at least three kinds DFM.
In one embodiment, be used for the present invention DFM include from one or more of subordinate bacterium (or
It is consisting essentially of, or be made from it):Bacillus (Bacillus), enterococcus spp (Enterococcus), piece coccus
Belong to (Pediococcus), saccharomyces (Saccharomyces), Bifidobacterium (Bifidobacterium), lactobacillus
(Lactobacillus), lactococcus (Lactococcus), aspergillus (Aspergillus) and combinations thereof.
DFM for the present invention can include the bacterium from one or more of following species (or substantially by it
Composition, or be made from it):Bacillus subtilis (Bacillus subtilis), bacillus licheniformis (Bacillus
Licheniformis), bacillus amyloliquefaciens (Bacillus amyloliquefaciens), Bacillus cercus
(Bacillus cereus), enterococcus faecium (Enterococcus faecium), Pediococcus acidilactici (Pediococcus
Acidilactici), saccharomyces cerevisiae (Saccharomyces cerevisiae), animal bifidobacteria animal subspecies
(Bifidobacterium animalis spp animalis), lactobacillus reuteri (Lactobacillus reuteri), mouse
Lee's sugar lactobacillus (Lactobacillus rhamnosus), Lactobacillus salivarius subspecies (Lactobacillus
Salivarius ssp salivarius), Lactobacillus farciminis (Lactobacillus farciminis), Lactococcus lactis
(Lactococcus lactis), clostridium butylicum (Clostridium butyricum), aspergillus oryzae (Aspergillus
Oryzae) and combinations thereof.
DFM for the present invention can include that one or more of following bacterial strain is (or consisting essentially of, or by it
Composition):Bacillus subtilis BS18 (NRRL B-50633), bacillus subtilis BS278 (NRRL 50634), bacillus subtilis
Bacterium 4-7d (NRRL B-50505), bacillus subtilis 3-5h (NRRL B-50507), bacillus subtilis AGTP BS3BP5
(NRRL B-50510), bacillus subtilis BS918 (NRRL B-50508), bacillus subtilis AGTP BS1013 (NRRL-
50509), bacillus subtilis AGTP 944 (NRRL B-50548), bacillus subtilis AGTP BS442 (NRRL B-
50542), bacillus subtilis AGTP BS1069 (NRRLB-50544), bacillus subtilis AGTP BS521 (NRRL B-
50545), bacillus subtilis BS2084 (NRRL B-50013), bacillus subtilis LSSA01 (NRRL B-50104), withered grass
Bacillus B27 (NRRL B-50105), bacillus subtilis 3A-P4 (PTA-6506), bacillus subtilis 15A-P4 (PTA-
6507), bacillus subtilis 22C-P1 (PTA-6508), bacillus subtilis BL21 (NRRL B-50134), lichens gemma bar
Bacterium BL21 (NRRL B-50134), bacillus licheniformis 3-12a (NRRL B-50504), bacillus licheniformis 4-2a (NRRL B-
50506), bacillus licheniformis 842 (NRRL B-50516), propionibacterium acide-propionici (Propionibacterium
Acidipropionici) P261 (NRRL B-50131), propionibacterium acide-propionici P179 (NRRLB-50133), propionibacterium acide-propionici
P169 (PTA 5271), propionibacterium acide-propionici P170 (PTA 5272), propionibacterium jensenii (Propionibacterium
Jensenii) P63 (NRRL B-30979), propionibacterium jensenii P195 (NRRL B-50132), Lactococcus lactis ID7 (PTA
6103), Lactococcus lactis JD19 (PTA 6104), lactobacillus acidophilus (Lactobacillus acidophilus) A2020
(NRRL B-30977), lactobacillus acidophilus A4000h (NRRL B-30978), lactobacillus acidophilus PIBc6 (NRRL B-50103),
Lactobacillus brevis (Lactobacillus brevis) LBR 1000 (NRRL B-30982), Lactobacillus casei (Lactobacillus
Casei) LC222 (NRRL B-30983), Yue Shi lactobacillus (Lactobacillus johnsonii) PLCB6 (NRRL B-
50518), Lactobacillus salivarius (Lactobacillus salivarius) o246i33w (NRRL B-50102), Lactobacillus brevis
AJ25 (PTA-6099), Lactobacillus brevis HE17 (PTA-6100), Lactobacillus brevis 1E-1 (PTA-6509), lactobacillus lactis
(Lactobacillus lactis) Cl15 (PTA-6101), lactobacillus lactis DJ6 (PTA-6102), Lactobacillus rhamnosus
(CNCM I-3698), Lactobacillus farciminis (CNCM I-3699), enterococcus faecium EF141 (EN-1) (NRRL B-30981), dung intestines
Coccus 2-1d (NRRL B-50519), Pediococcus acidilactici PIJe3 (NRRL B-50101), Pediococcus acidilactici o246e42 (NRRL
B-50171) and combinations thereof.
DFM for the present invention can include more than one, suitably two or more, suitably at least three kinds of bacillus
Species (Bacillus spp).
DFM for the present invention can include that one or more of following bacterial strain is (or consisting essentially of, or by it
Composition):Bacillus subtilis strain 3A-P4 (PTA-6506), 15A-P4 (PTA-6507), 22C-P1 (PTA-6508), 2084
(NRRL B-500130), LSSA01 (NRRL-B-50104), BS27 (NRRL B-50105), BS 18 (NRRL B-50633) and
BS 278 (NRRL B-50634) or combinations thereof.
In one embodiment, the DFM for being used for the present invention can include that one or more of following bacterial strain is (or basic
On be made from it, or be made from it):Bacillus subtilis strain 15A-P4 (PTA-6507), 2084 (NRRL B-500130),
LSSA01(NRRL-B-50104)。
In one embodiment, the phytase for the present invention is six phosphorus of 6-phytase or 3- inositols
Sour enzyme, preferably 6-phytase.
In one embodiment, the phytase for the present invention can be selected from:Escherichia coli phytic acid
Enzyme or Buttiauxella (Buttiauxella) phytase or six phosphorus of Citrobacter (Citrobacter) inositol
Sour enzyme or Hafnia (Hafnia) phytase or aspergillus phytase or Penicillium
(Penicillium) phytase or trichoderma (Trichoderma) phytase or Escherichia coli inositol six
Phosphatase or Hansenula (Hansenula) phytase, or combinations thereof.
In one embodiment, the phytase for the present invention can be one or more in following
6-phytase:Escherichia coli, Buttiauxella species (Buttiauxella spp) or citric acid bacterium species
(Citrobacter spp), such as Bu Shi citric acid bacteriums (Citrobacter braakii), including a combination thereof.
Expediently, the phytase for the present invention can be one or more PhyzymeXPTM、AxtraPhyTM,
Or Ronozyme HiPhosTMOr QuantumTMOr Quantum BlueTM。
Expediently, phytase can be more than one phytases, such as at least two kinds of or at least three kinds of inositols
The mixture of six-phosphatase.
In one embodiment, it is preferred to ground, the phytase (example active at a low ph for the present invention
Such as, active between pH2 and pH5.5).
In one embodiment, it is preferred to ground, the phytase for the present invention has the optimal pH (example under low pH
Such as, with the optimal pH in the range of pH2 and pH5.5).
In one embodiment, there is clinical or subclinical enteropathy attack in individual.
In one embodiment, the attack of clinical or subclinical enteropathy can be by arbitrary pathogen or arbitrary pathogenic bacteria (such as
C.perfringens or Escherichia coli) cause.
In one embodiment, in feed addictive composition Direct-Fed Microbials dosage can from
3.8x103CFU DFM:1FTU enzymes are to 2.0x105CFU:In the range of 1FTU enzymes.
Direct-Fed Microbials (DFM)
Term " microorganism (microbial) " herein can be used interchangeably with " microbial body (microorganism) ".
Preferably, DFM includes viable microbial.Preferably, DFM includes bacterium living or viable yeast or fungi living.
Preferably, DFM includes bacterium living.
Term " viable microbial " means the microorganism that has metabolic activity or can break up.
In one embodiment, DFM can be spore forming bacteria, therefore term DFM can be by spore, such as bacterium spore
Son composition, or contain spore, such as bacterial spore.Therefore, in one embodiment, the term as used herein " viable microbial "
May include microbial spore, such as endospore or conidium.
In another embodiment, the DFM in feed addictive composition of the invention is by microbial spore, such as
Endospore or conidium composition, or do not contain microbial spore, such as endospore or conidium.
Microorganism can be naturally occurring microorganism or its can be microbial.Microorganism can also be suitable micro-
The combination of biology.
In some respects, DFM of the invention can be it is following in it is one or more:Bacterium, yeast, fungi.
Preferably, DFM of the invention is probiotic microorganisms.
In the present invention, term Direct-Fed Microbials (DFM) cover Direct-fed bacterium, Direct-fed yeast, directly
Feed fungi and combinations thereof.
Preferably, DFM is Direct-fed bacterium.
Preferably, DFM is the combination for including two or more bacteriums (such as three kinds or a variety of or four kinds or a variety of);Or
Person DFM is the combination for including two or more bacterium bacterial strains (such as three kinds or a variety of or four kinds or a variety of).
Preferably, bacterium is separation.
Expediently, DFM can include from the bacterium of one or more of subordinate:Lactobacillus, lactococcus, chain
Coccus (Streptococcus), bacillus, Pediococcus, enterococcus spp, Leuconostoc (Leuconostoc), meat
Eat Bacillus (Carnobacterium), Propionibacterium (Propionibacterium), Bifidobacterium, fusobacterium and huge
Spherical Pseudomonas (Megasphaera) and combinations thereof.
In one embodiment, DFM can be selected from following Bacillus spec:Bacillus subtilis, wax-like gemma
Bacillus, bacillus licheniformis, bacillus amyloliquefaciens and bacillus pumilus (Bacillus pumilus).
In one embodiment, DFM can be Bacillus strain.
In one embodiment, DFM can be selected from:
Bacillus subtilis BS18 (NRRL B-50633), bacillus subtilis BS278 (NRRL50634), withered grass gemma
Bacillus 4-7d (NRRL B-50505), bacillus subtilis 3-5h (NRRL B-50507), bacillus subtilis AGTP BS3BP5
(NRRL B-50510), bacillus subtilis BS918 (NRRL B-50508), bacillus subtilis AGTP BS1013 (NRRL-
50509), bacillus subtilis AGTP 944 (NRRL B-50548), bacillus subtilis AGTP BS442 (NRRL B-
50542), bacillus subtilis AGTP BS1069 (NRRL B-50544), bacillus subtilis AGTP BS521 (NRRL B-
50545), bacillus subtilis BS2084 (NRRL B-50013), bacillus subtilis LSSA01 (NRRL B-50104), withered grass
Bacillus B27 (NRRL B-50105), bacillus subtilis 3A-P4 (PTA-6506), bacillus subtilis 15A-P4 (PTA-
6507), bacillus subtilis 22C-P1 (PTA-6508), bacillus subtilis BL21 (NRRL B-50134) and combinations thereof.
To avoid generating query, bacillus subtilis LSSA01 (NRRL B-50104) is sometimes referred to as bacterial strain BS8.
In one embodiment, DFM can be selected from:
Bacillus subtilis strain AGTP BS 1068 (NRRL B-50543) or bacillus pumilus KX11-1 (NRRL
B-50546) and combinations thereof.
In one embodiment, DFM is selected from:
Bacillus licheniformis BL21 (NRRL B-50134), bacillus licheniformis 3-12a (NRRL B-50504), lichens bud
Spore bacillus 4-2a (NRRL B-50506) and bacillus licheniformis 842 (NRRL B-50516).
In one embodiment, DFM can be the combination for including two or more Bacillus strains.
In one embodiment, DFM can be two or more bacillus subtilis strains 3A-P4 (PTA-6506),
15A-P4(PTA-6507)、22C-P1(PTA-6508)、2084(NRRL B-500130)、LSSA01(NRRL-B-50104)、
The combination of BS27 (NRRL B-50105), BS 18 (NRRL B-50633) and BS 278 (NRRL B-50634).
In preferred embodiments, DFM can include that one of following combination is (or consisting essentially of, or by its group
At):
Bacillus subtilis LSSA01 (NRRL B-50104)+bacillus subtilis BS18 (NRRL B-50633)+withered grass
Bacillus 22C-P1 (PTA-6508);Or
Bacillus subtilis LSSA01 (NRRL B-50104)+bacillus subtilis 3A-P4 (PTA-6506)+withered grass gemma
Bacillus BS2084 (NRRL B-50013);Or
Bacillus subtilis LSSA01 (NRRL B-50104)+bacillus subtilis 3A-P4 (PTA-6506)+withered grass gemma
Bacillus BS2084 (NRRL B-50013)+bacillus subtilis 15A-P4 (PTA-6507);Or
Bacillus subtilis 3A-P4 (PTA-6506)+bacillus subtilis 22C-P1 (PTA-6508)+bacillus subtilis
BS2084(NRRL B-50013);Or
Bacillus subtilis LSSA01 (NRRL B-50104)+bacillus subtilis 15A-P4 (PTA-6507)+withered grass bud
Spore bacillus BS2084 (NRRL B-50013);Or
Bacillus subtilis 3A-P4 (PTA-6506)+bacillus subtilis BS18 (NRRL B-50633)+bacillus subtilis
Bacterium 22C-P1 (PTA-6508);Or
Bacillus subtilis 3A-P4 (PTA-6506)+bacillus subtilis BS2084 (NRRL B-50013)+withered grass gemma
Bacillus BS278 (NRRL 50634).
Bacterial strain 3A-P4 (PTA-6506), 15A-P4 (PTA-6507) and 22C-P1 (PTA-6508) can be trained from U.S. typical case
Support the open acquisition of object collection (American Type Culture Collection, ATCC).
Bacterial strain 2084 (NRRL B-500130), LSSA01 (NRRL-B-50104), BS27 (NRRL B-50105) can be from U.S.s
Agricultural research institute of state collection (Agricultural Research Service Culture Collection, NRRL)
It is open to obtain.Strains B. subtilis LSSA01 is sometimes referred to as bacillus subtilis 8.
These bacterial strains are instructed in US 7,754,469B2.
Danisco u s company (Danisco USA Inc.) (W227N752Westmound Dr.Waukesha, WI
53186, USA) following preserved material is preserved in american agriculture research aircraft according further to budapest treaty (Budapest Treaty)
Structure collection (1815North University Street, Peoria, Illinois 61604, United States of
America), the preservation date and preserving number of original deposit is detailed below:
Bacillus licheniformis 3-12a | NRRL B-50504 | On May 13rd, 2011 |
Bacillus licheniformis 4-2a | NRRL B-50506 | On May 13rd, 2011 |
Bacillus licheniformis BL842 | NRRL B-50516 | On May 20th, 2011 |
Bacillus pumilus AGTP KXII-1 | NRRL B-50546 | On August 5th, 2011 |
Bacillus pumilus AGTP BS1068 | NRRL B-50543 | On August 4th, 2011 |
Bacillus subtilis BS18 | NRRL B-50633 | On January 9th, 2012 |
Bacillus subtilis BS278 | NRRL B-50634 | On January 9th, 2012 |
Bacillus subtilis 4-7d | NRRL B-50505 | On May 13rd, 2011 |
Bacillus subtilis 3-5h | NRRL B-50507 | On May 13rd, 2011 |
Bacillus subtilis AGTP BS3BP5 | NRRL B-50510 | On May 13rd, 2011 |
Bacillus subtilis AGTP BS918 | NRRL B-50508 | On May 13rd, 2011 |
Bacillus subtilis AGTP BS1013 | NRRL B-50509 | On May 13rd, 2011 |
Bacillus subtilis AGTP 944 | NRRL B-50548 | On August 11st, 2011 |
Bacillus subtilis AGTP BS442 | NRRL B-50542 | On August 4th, 2011 |
Bacillus subtilis AGTP BS1069 | NRRL B-50544 | On August 4th, 2011 |
Bacillus subtilis AGTP BS521 | NRRL B-50545 | On August 4th, 2011 |
Danisco u s company (Danisco USA Inc.) (W227N752Westmound doctors Waukesha, WI
53186, the U.S.) authorize DuPont Nutrition BioSciences Co., Ltd. (DuPont Nutrition Biosciences ApS)
(Langebrogade 1, PO Box 17, DK-1001, Copenhagen K, Denmark) refers to these guarantors in the present patent application
The biomaterial of Tibetan, and agree to the sky and that irrevocablely the public can get the material of institute preservation.
In some embodiments, DFM can be the combination for including the bacillus subtilis strain being described in detail in following table.
In one embodiment, DFM can be selected from lactococcus species (Lactococcus spp).
In one embodiment, DFM can be selected from one or more in following lactococcus species:Butterfat galactococcus
(Lactococcus cremoris) and Lactococcus lactis and combinations thereof.
In one embodiment, DFM can be selected from following bacterial strain or combinations thereof:
Lactococcus lactis ID7 | PTA 6103 |
Lactococcus lactis JD19 | PTA 6104 |
In one embodiment, DFM can be Lactobacillus species (Lactobacillus spp).
In one embodiment, DFM can be selected from following Lactobacillus species:Lactobacillus buchneri (Lactobacillus
Buchneri), lactobacillus acidophilus, Lactobacillus casei, Kefir grains lactobacillus (Lactobacillus kefiri), double qi lactobacillus
(Lactobacillus bifidus), Lactobacillus brevis, Lactobacillus helveticus (Lactobacillus helveticus), class cheese
Lactobacillus (Lactobacillus paracasei), Lactobacillus rhamnosus, Lactobacillus salivarius, lactobacillus curvatus
(Lactobacillus curvatus), lactobacillus bulgaricus (Lactobacillus bulgaricus), Lactobacillus saki
(Lactobacillus sakei), lactobacillus reuteri, lactobacillus fermenti (Lactobacillus fermentum), sausage breast bar
Bacterium, lactobacillus lactis, Lactobacillus delbrueckii (Lactobacillus delbreuckii), lactobacillus plantarum (Lactobacillus
Plantarum), class lactobacillus plantarum (Lactobacillus paraplantarum), Lactobacillus farciminis, Lactobacillus rhamnosus,
Lactobacillus crispatus (Lactobacillus crispatus), Lactobacillus gasseri (Lactobacillus gasseri), Yue Shi breasts
Bacillus and Lactobacillus Jensenii (Lactobacillus jensenii) and its arbitrary combination.
In one embodiment, DFM is selected from following bacterial strain or combinations thereof:
Lactobacillus acidophilus A2020 | NRRL B-30977 |
Lactobacillus acidophilus A4000h | NRRL B-30978 |
Lactobacillus acidophilus PIBc6 | NRRL B-50103 |
Lactobacillus brevis LBR 1000 | NRRL B-30982 |
Lactobacillus casei LC222 | NRRL B-30983 |
Yue Shi lactobacillus PLCB6 | NRRL B-50518 |
Lactobacillus salivarius o246i33w | NRRL B-50102 |
Lactobacillus brevis AJ25 | PTA-6099 |
Lactobacillus brevis HE17 | PTA-6100 |
Lactobacillus brevis 1E-1 | PTA-6509 |
Lactobacillus lactis Cl15 | PTA-6101 |
Lactobacillus lactis DJ6 | PTA-6102 |
Lactobacillus rhamnosus | CNCM I-3698 |
Lactobacillus farciminis | CNCM I-3699 |
In one embodiment, DFM can be selected from one or more of following bacterial strain:Lactobacillus rhamnosus CNCM-
I-3698 and Lactobacillus farciminis CNCM-I-3699.These bacterial strains by Sorbial (Route de Spay 72700Allonnes,
France) French Organism Depositary (Collection Nationale de Cultures are deposited on December 8th, 2006
De Microorganims) (CNCM) (25, Rue due Docteur Roux, F75724Paris Cedex 15, France), it protects
Hide object all authority, ownership and interests be subsequently transferred to Danisco France SAS (20, Rue de Brunel,
75017Paris, France).
Danisco France SAS authorize DuPont Nutrition BioSciences Co., Ltd. (Langebrogade1, PO Box
17, DK-1001, Copenhagen K, Denmark) in the present patent application with reference to the biomaterial of these preservations, and without reserve
Ground and irrevocable the material public for agreeing to institute's preservation can get.
In one embodiment, DFM can be can be from Danisco Animal nutrition company (Danisco Animal
Nutrition it) obtainsProduct.
In one embodiment, DFM can come from Pediococcus.
In one embodiment, DFM can come from following Pediococcus species:Pediococcus acidilactici, such as following lactic acid sheet
It is one or more in meningitidis strains PIJe3 (NRRL B-50101) or o246e42 (NRRL B-50171).
In one embodiment, DFM can be selected from following Bifidobacteria (Bifidobacteria spp):Breast
Bifidobacterium (Bifidobacterium lactis), bifidobacterium bifidum (Bifidobacterium bifidium), length are double
Discrimination bacillus (Bifidobacterium longum), B. animais (Bifidobacterium animalis), short bifid
Bacillus (Bifidobacterium breve), bifidobacterium infantis (Bifidobacterium infantis), chain bifid bar
Bacterium (Bifidobacterium catenulatum), false chain Bifidobacterium (Bifidobacterium
Pseudocatenulatum), bifidobacterium adolescentis (Bifidobacterium adolescentis) and angle Bifidobacterium
(Bifidobacterium angulatum) and its arbitrary combination.
In one embodiment, DFM can be Enterococcus species (Enterococcus spp).
In one embodiment, DFM can come from enterococcus faecium species.
In one embodiment, DFM can be selected from enterococcus faecium EF141 (EN-1) (NRRL B-30981), dung intestines ball
Bacterium 2-1d (NRRL B-50519) and combinations thereof.
In one embodiment, DFM can come from Propionibacterium.
In one embodiment, DFM can be selected from following Propionibacterium species or combinations thereof:Propionibacterium acide-propionici and
Propionibacterium jensenii.
In one embodiment, DFM can be selected from following Propionibacterium species or combinations thereof:
Propionibacterium acide-propionici P261 | NRRL B-50131 |
Propionibacterium acide-propionici P179 | NRRL B-50133 |
Propionibacterium acide-propionici P169 | PTA 5271 |
Propionibacterium acide-propionici P170 | PTA 5272 |
Propionibacterium jensenii P63 | NRRL B-30979 |
Propionibacterium jensenii P195 | NRRL B-50132 |
Expediently, DFM can include the bacterium from one or more of following species:Bacillus subtilis, lichens
Bacillus, bacillus amyloliquefaciens, enterococcus faecium, Enterococcus species and Pediococcus species (Pediococcus spp),
It is Lactobacillus species, Bifidobacteria, lactobacillus acidophilus, Pediococcus acidilactici, Lactococcus lactis, bifidobacterium bifidum, withered
Careless bacillus, Te Shi Propionibacteriums (Propionibacterium thoenii), Lactobacillus farciminis, Lactobacillus rhamnosus, angstrom
Family name's Megasphaera (Megasphaera elsdenii), clostridium butylicum, B. animais animal subspecies, lactobacillus reuteri, wax
Shape bacillus, Lactobacillus salivarius subspecies, Propionibacterium species (Propionibacteria sp) and combinations thereof.
Direct-fed bacterium for the present invention may belong to same type (genus and species and bacterial strain) or can include genus and species
And/or the mixture of bacterial strain.
Expediently, the DFM of the present invention can be product or the microorganism being contained in those products those of in following table
In it is one or more:
In one embodiment, expediently, DFM can be
It can be bought from Danisco A/S BJ Rep Office, be 2084 preserving number NRRl B- of Bacillus strain
50013, Bacillus strain LSSAO1 preserving numbers NRRL B-50104 and Bacillus strain 15A-P4ATCC preserving numbers
The combination (as taught in US 7,754,469B --- be hereby incorporated by reference) of PTA-6507.
In one embodiment, DFM can be bacillus licheniformis BL21 (NRRL B-50134).
AgTech Products, Inc. (W227N752Westmound Drive, Waukesha, WI53186, the U.S.) are pressed
Following biological deposit is preserved in american agriculture research institution collection (NRRL) according to budapest treaty, original is detailed below
The preservation date and preserving number of beginning preserved material:
Bacillus licheniformis BL21 | NRRL B-50134 | On April 15th, 2008 |
Enterococcus faecium EF141 (EN-1) | NRRL B-30981 | On October 30th, 2006 |
Enterococcus faecium 2-1d | NRRL B-50519 | On June 3rd, 2011 |
Lactobacillus acidophilus A2020 | NRRL B-30977 | On October 24th, 2006 |
Lactobacillus acidophilus A4000h | NRRL B-30978 | On October 24th, 2006 |
Lactobacillus acidophilus PIBc6 | NRRL B-50103 | On January 18th, 2008 |
Lactobacillus brevis LBR 1000 | NRRL B-30982 | On October 30th, 2006 |
Lactobacillus casei LC222 | NRRL B-30983 | On October 30th, 2006 |
Yue Shi lactobacillus PLCB6 | NRRL B-50518 | On June 3rd, 2011 |
Lactobacillus salivarius o246i33w | NRRL B-50102 | On January 18th, 2008 |
Pediococcus acidilactici PIJe3 | NRRL B-50101 | On January 18th, 2008 |
Pediococcus acidilactici o246e42 | NRRL B-50171 | On August 29th, 2008 |
AgTech Products, Inc authorize DuPont Nutrition BioSciences Co., Ltd. (Langebrogade 1, PO Box
17, DK-1001, Copenhagen K, Denmark) in the present patent application with reference to the biomaterial of these preservations, and without reserve
Ground and irrevocable the material public for agreeing to institute's preservation can get.
AgTech Products, Inc. (W227N752Westmound Drive, Waukesha, WI53186, the U.S.) are also
According to budapest treaty by following biological deposit be preserved in American type culture collection (ATCC) (Manassas,
VA 20110-2209, the U.S.) (PTA references) or american agriculture research institution collection (NRRL references), it is detailed below original
The preservation date and preserving number of preserved material --- these bacterial strains are mentioned in listed patent in the table, therefore are open can get
Bacterial strain:
In one embodiment, the DFM for the present invention is selected from:Bacillus subtilis BS18 (NRRL B-50633),
Bacillus subtilis BS278 (NRRL 50634), bacillus subtilis 4-7d (NRRL B-50505), bacillus subtilis 3-5h
(NRRL B-50507), bacillus subtilis AGTP BS3BP5 (NRRL B-50510), bacillus subtilis BS918 (NRRL
B-50508), bacillus subtilis AGTP BS1013 (NRRL-50509), (the NRRL B- of bacillus subtilis AGTP 944
50548), bacillus subtilis AGTP BS442 (NRRL B-50542), bacillus subtilis AGTP BS1069 (NRRL B-
50544), bacillus subtilis AGTP BS521 (NRRL B-50545), bacillus subtilis BS2084 (NRRL B-50013),
Bacillus subtilis LSSA01 (NRRL B-50104), bacillus subtilis B 27 (NRRL B-50105), bacillus subtilis
It is 3A-P4 (PTA-6506), bacillus subtilis 15A-P4 (PTA-6507), bacillus subtilis 22C-P1 (PTA-6508), withered
Careless bacillus BL21 (NRRL B-50134), bacillus licheniformis BL21 (NRRL B-50134), bacillus licheniformis 3-12a
(NRRL B-50504), bacillus licheniformis 4-2a (NRRL B-50506), bacillus licheniformis 842 (NRRL B-50516),
Propionibacterium acide-propionici P261 (NRRL B-50131), propionibacterium acide-propionici P179 (NRRL B-50133), propionibacterium acide-propionici
P169 (PTA 5271), propionibacterium acide-propionici P170 (PTA 5272), propionibacterium jensenii P63 (NRRL B-30979), Zhan Shi
Propionibacterium P195 (NRRL B-50132), Lactococcus lactis ID7 (PTA 6103), Lactococcus lactis JD19 (PTA 6104),
Lactobacillus acidophilus A2020 (NRRL B-30977), lactobacillus acidophilus A4000h (NRRL B-30978), lactobacillus acidophilus PIBc6
(NRRL B-50103), Lactobacillus brevis LBR 1000 (NRRL B-30982), Lactobacillus casei LC222 (NRRL B-30983),
Yue Shi lactobacillus PLCB6 (NRRL B-50518), Lactobacillus salivarius o246i33w (NRRL B-50102), Lactobacillus brevis AJ25
(PTA-6099), Lactobacillus brevis HE17 (PTA-6100), Lactobacillus brevis 1E-1 (PTA-6509), lactobacillus lactis Cl15 (PTA-
6101), lactobacillus lactis DJ6 (PTA-6102), Lactobacillus rhamnosus (CNCM I-3698), Lactobacillus farciminis (CNCM I-
3699), enterococcus faecium EF141 (EN-1) (NRRL B-30981), enterococcus faecium 2-1d (NRRL B-50519), Pediococcus acidilactici
PIJe3 (NRRL B-50101), Pediococcus acidilactici o246e42 (NRRL B-50171) and combinations thereof.
Expediently, DFM can include the yeast from Blastocystis species (Saccharomyces spp).
Preferably, wait for that DFM is it has been generally acknowledged that safety and the microorganism preferably ratified through GRAS used according to the present invention.
Those skilled in the art will readily recognize that from for food and/or agricultural and it has been generally acknowledged that suitable for animal food
The specific species and/or bacterial strain of microorganism in category described herein.
Preferably, DFM used according to the invention is adapted for the DFM of animal edible.
Advantageously, if product is feed or feed addictive composition, DFM living should provide feed or feeding in retailer
Feed additives composition keeps effective for normal " the guaranteeing the quality " of the entire product of sale or during " effective " date.It is desired
Time span and normal shelf life will be different because of feed difference, and those skilled in the art will recognize that shelf life will
The difference depending on feed type, feed size, storage temperature, treatment conditions, packaging material and packaging facilities.
In some embodiments, it is important that DFM is resistant to be heated, and is heat-resisting.By feed pill
(pelleted) especially true in the case of.Therefore, in one embodiment, DFM can be themoduric, such as heat-resisting
Bacterium, including such as Bacillus spec.
In some embodiments, it may be preferred that DFM is spore-bearing bacterium, such as bacillus, such as bacillus
Species.When growth conditions is unfavorable, bacillus can form stable endospore, and it to heat, pH, moisture and disappears
Toxic agent has extremely strong resistance.
In one embodiment, expediently, DFM can reduce or prevent pathogenic microorganisms (such as C.perfringens and/or
Escherichia coli and/or Salmonella ssp and/or campylobacter species, preferably C.perfringens and/or Escherichia coli)
It colonizes in the intestine.
The DFM of the present invention can be the DFM of any suitable.In one embodiment, " DFM surveys can be measured with following
It is fixed " determine that microorganism becomes the adaptability of DFM.To avoid generating query, in one embodiment, according to teaching herein
" DFM measurement " be selected as inhibition bacterial strain (or antipathogen DFM) DFM be suitable for the present invention (i.e. according to the present invention
Feed addictive composition) DFM.
DFM is measured:
Pipe is inoculated with by the representative pathogens body from representative cluster.
Into the pipe being inoculated with, addition is from a manner of aerobic or the supernatant of the potential DFM of anaerobism mode culture, and is incubated.
After incubation, for the optical density (OD) of each cause of disease bulk measurement control tube and supernatant processing tube.
The bacterium colony for generating (potential DFM) bacterial strain for reducing OD compared with the control is classified as inhibition bacterial strain (or disease-resistant original
Body DFM).
DFM used herein is illustrated in more detail in US2009/0280090 (being hereby incorporated by reference) to measure.
Preferably, it is one of the following (or multiple) for the representative pathogens body of measurement:Fusobacterium, such as perfringens
Clostridium and/or clostridium difficile and/or Escherichia coli and/or Salmonella ssp and/or campylobacter species.At one
In preferred embodiment, the measurement is carried out with one or more in following:C.perfringens and/or clostridium difficile and/or
Escherichia coli, preferably C.perfringens and/or clostridium difficile, more preferable C.perfringens.
In one embodiment, DFM of the invention is preferably antipathogen.
The term as used herein " antipathogen " means that DFM offsets the effect (such as negative effect) of pathogen.
In one embodiment, for determine DFM whether be the present invention antipathogen, can be measured using above-mentioned DFM.
If DFM is classified as inhibition bacterial strain in above-mentioned " DFM measurement ", especially when pathogen is C.perfringens, then
DFM is considered as antipathogen or antipathogen DFM.
In one embodiment, antipathogen DFM can be one or more in following bacterium:
Bacillus subtilis strain 2084, preserving number NRRl B-50013,
Bacillus subtilis strain LSSAO1, preserving number NRRL B-50104;
Bacillus subtilis strain 15A-P4, ATCC preserving number PTA-6507;
Bacillus subtilis 3A-P4, ATCC preserving number PTA-6506;With
Bacillus subtilis strain BS27, ATCC preserving number NRRL B-50105.
To avoid generating query, these bacterial strains are obtainable, and are referred in US 7,754,459B.
In one embodiment, DFM used according to the invention is not the preserving number taught in WO2008/016214
For 17 bacterial strains of Lactobacillus gasseri BNR of KCTC 10902BP.
Preferably, DFM is not inactivation microorganism.
In one embodiment, it is the group for including one or more DFM microorganisms as described herein used herein of DFM
Close object.The composition can additionally comprise the enzyme of the present invention.
It can be fed the composition as Direct-Fed Microbials (DFM) to animal.
One or more carriers or other compositions can be added into DFM.
DFM can be presented with various physical forms, for example, in the form of surface charging (top dress), it is for animals for use as liquid
Draught or to be added to water-soluble concentrate, gelatine capsule or the gel form in newborn substitute.
In an embodiment of surface dosing form, by the tunning of freeze-drying be added to carrier (such as breast
Clearly, maltodextrin, sucrose, dextrose, lime stone (calcium carbonate), rice husk, yeast culture, dry starch and/or sodium silicoaluminate)
In.
It, will in for an embodiment of liquid drencs or the water-soluble concentrate of newborn substitute replenishers
The tunning of freeze-drying is added to water-solubility carrier (such as whey, maltodextrin, sucrose, dextrose, dry starch, silicon
Sodium aluminate) in, and adding liquid is to form drencs or into breast or newborn substitute add replenishers.
In an embodiment of hard gelatin capsule forms, by the tunning of freeze-drying be added to carrier (such as whey,
Maltodextrin, sugar, lime stone (calcium carbonate), rice husk, yeast culture, dry starch and/or sodium silicoaluminate) in.
In one embodiment, bacterium and carrier are closed in degradable gelatine capsule.At one of gel form
In embodiment, the tunning of freeze-drying is added to carrier (such as vegetable oil, sucrose, silica, polysorbate
80, propylene glycol, butylated hydroxyanisol, citric acid, ethoxyquin (ethoxyquin) and/or artificial tanning agent) in formed
Gel.
DFM can (include but not limited to optionally growth substrate, enzyme, sugar, carbohydrate, extract and growth promotion with additive
Micro- ingredient) drying agent mixing.Sugar may include following:Lactose, maltose, dextrose, maltodextrin, glucose, fruit
Sugar, mannose, Tagatose (tagatose), sorbose, gossypose and galactolipin.Alone or in combination form sugar ranging from
50-95%.Extract may include yeast or dry yeast fermentation solubles, ranging from 5-50%.Growth substrate may include:Pancreas egg
White casein hydrolysis, ranging from 5-25%;Sodium lactate, ranging from 5-30%;And Tween 80, ranging from 1-5%.Carbohydrate can
Including mannitol, sorbierite, adonite and arabitol.The ranging from 5-50% of the carbohydrate of form alone or in combination.It is micro- at
Point it may include following:Calcium carbonate, ranging from 0.5-5.0%;Calcium chloride, ranging from 0.5-5.0%;Dipotassium hydrogen phosphate, ranging from
0.5-5.0%;Calcium phosphate, ranging from 0.5-5.0%;Albumen manganese, ranging from 0.25-1.00%;And manganese, ranging from 0.25-
1.0%.
It, can be by one or more cultures and one or more carriers (if if use) to prepare DFM as described herein
It is added to belt or arm mixer, and is mixed about 15 minutes, but the time can be increased or decreased.Each component is mixed so that producing
The homogeneous mixture of raw culture and carrier.The preferably dry flowable powder of final product.Then by DFM or DFM can be included
Composition be added in animal feed or feed premix, be added in the water of animal, or with it is known in the art other
Mode application (is preferably administered simultaneously with the enzyme of the present invention).One or more DFM or as described herein groups as described herein can be used
It closes object and supplements animal feed.
" mixtures of at least two bacterial strains " mean two kinds, three kinds, four kinds, five kinds, six kinds or even more a variety of bacterial strains
Mixture.In some embodiments of the mixture of bacterial strain, ratio can be changed to 99% from 1%.The mixture of bacterial strain its
His embodiment is 25% to 75%.The other embodiments of the mixture of bacterial strain are that each bacterial strain is about 50%.Mixed
When closing object comprising two or more bacterial strains, ratio or be present in mixture in varing proportions that bacterial strain can be substantially equal.
In one embodiment, DFM can be the alive or dead microorganism used in the form of detaching or is semi-detached.
DFM can be combined with the growth medium for cultivating it wherein or not combined.
In one embodiment, when cultivating on appropriate media, DFM can generate Colony Forming Unit.This is appropriate
Medium can include feed or feed ingredient (or being made from it).
In one embodiment, when cultivating on appropriate media, DFM cannot generate Colony Forming Unit.This is suitably situated between
Matter can include feed or feed ingredient (or being made from it).
Whether can or can not generate that Colony Forming Unit --- cell still may be used when no matter DFM is cultivated on appropriate media
With with metabolic activity (for example, even if they cannot be separated).
In one embodiment, DFM can be used as dead cell to apply.
In one embodiment, DFM can be used as viable microbial to apply.
DFM can be properly joined into.
Expediently, the dosage of DFM can be between about 1 × 10 in feed3CFU/g feeds are to about 1 × 109Between CFU/g feeds,
Suitably between about 1 × 104CFU/g feeds are to about 1 × 108Between CFU/g feeds, suitably between about 7.5 × 104CFU/g is raised
Expect to about 1 × 107Between CFU/g feeds.
In one embodiment, DFM is by more than about 1 × 103CFU/g feeds are suitably more than about 1 × 104CFU/g
Feed is suitably more than about 7.5 × 104CFU/g feeds are added in feed.
Expediently, the dosage of DFM can be between about 2 × 10 in feed addictive composition2CFU/g compositions to about 1 ×
1010Between CFU/g compositions, suitably between about 1 × 103CFU/g compositions are to about 1 × 1010Between CFU/g compositions, fit
Preferably between about 1 × 104CFU/g compositions are to about 1 × 109Between CFU/g compositions, suitably between about 3.75x104CFU/g
Composition is to about 3x108Between CFU/g compositions.
In one embodiment, DFM is by more than about 1 × 105CFU/g compositions are suitably more than about 1 × 106CFU/
G compositions are suitably more than about 3.75 × 107CFU/g compositions are added in feed addictive composition.
The term as used herein " CFU " means Colony Forming Unit, and is the measurement of living cells, and wherein bacterium colony represents source
From the cell aggregation of single progenitor cells.
Phytase
The term as used herein " phytase " refers to the phosphoric acid that catalysis includes phytate and phytic acid
Ester hydrolysis and the enzyme (i.e. the polypeptide with phytase activity) for discharging inorganic phosphate.
For the present invention phytase can be divided into 6-phytase (being classified as E.C.3.1.3.26) or
3-Phytase (is classified as E.C.3.1.3.8).
In one embodiment, phytase can be 6-phytase (E.C.3.1.3.26).
In a preferred embodiment, the phytase for the present invention can be one in following commercial product
One or more phytases in planting or being a variety of:
The term as used herein shares gene and means that the DNA vector for inverting biological body contains the conjunction based on consensus sequence
At phytic acid enzyme gene, from the URA genes of non-pathogenic yeast saccharomyces cerevisiae and answering for escherichia coli plasmid pBR322
Starting point processed.
In one embodiment, phytase is Citrobacter phytase, is originated from:Such as
Disclosed in WO2006/038062 (being hereby incorporated by reference) and WO2006/038128 (being hereby incorporated by reference) not
Family name's citric acid bacterium (Citrobacter freundii), preferably Citrobacter freundii NCIMB 41247 and its variant;WO
Bu Shi citric acid bacteriums YH-15 disclosed in 2004/085638;Bu Shi citric acids disclosed in WO2006/037328 are thin
Bacterium ATCC51113 (being hereby incorporated by reference) and its in such as WO2007/112739 (being hereby incorporated by reference) and
Variant disclosed in WO2011/117396 (being hereby incorporated by reference);WO2006037327 (is hereby incorporated by reference)
Disclosed in without malonic acid citric acid bacterium (Citrobacter amalonaticus), preferably without malonic acid citric acid bacterium
ATCC 25405 or without malonic acid citric acid bacterium ATCC 25407;Institute is public in WO2006037327 (being hereby incorporated by reference)
The Ji Shi citric acid bacteriums (Citrobacter gillenii) opened, preferably Ji Shi citric acid bacteriums DSM13694;Or intermediate lemon
Lemon acetic bacterial (Citrobacter intermedius), kirschner citric acid bacterium (Citrobacter koseri), muroid lemon
Acetic bacterial (Citrobacter murliniae), rodent citric acid bacterium (Citrobacter rodentium), Sai Lake
Family name's citric acid bacterium (Citrobacter sedlakii), fertile gram Mans citric acid bacterium (Citrobacter werkmanii),
The polypeptide or its variant of poplar Ge Shi citric acid bacteriums (Citrobacter youngae), citric acid bacterium species.
In one embodiment, phytase can come from Citrobacter, such as from Freund lemon
The phytase of acetic bacterial, the phytase as taught in WO2006/038128, the bibliography are incorporated herein
As reference.
In preferred embodiments, phytase is preferably by Danisco A/S BJ Rep Office with trade name Phyzyme
XPTMThe escherichia coli phytase of sale.
Alternatively, phytase can be Buttiauxella phytase, such as Buttiauxella agrestis
(Buttiauxella agrestis) phytase, such as WO 2006/043178, WO2008/097619, WO2009/
129489, it is taught in WO2006/038128, WO2008/092901, PCT/US2009/41011 or PCT/IB2010/051804
The phytase led, all patents are hereby incorporated by reference.
On the one hand, enzyme used is polypeptide shown in BP17 or SEQ ID No.1 or SEQ ID No.2 or its change
Body, such as therewith at least 70% homogeneity, preferably therewith at least 75% homogeneity, preferably therewith at least 80% together
One property, preferably therewith at least 85% homogeneity, preferably therewith at least 90% homogeneity, preferably therewith at least
95% homogeneity, preferably therewith at least 96% homogeneity, preferably therewith at least 97% homogeneity, preferably have therewith
At least 98% homogeneity, the sequence preferably therewith at least 99% homogeneity.BP17 is six phosphorus of Buttiauxella species inositol
The enzyme variants of sour enzyme, and be described in such as WO2008/097619, which is hereby incorporated by reference.
In one embodiment, enzyme used is BP17, and is described in such as WO2008/097619.BP17 is cloth
The enzyme variants of mound Salmonella species phytase.
The sequence (excluding signal peptide) of BP17 is shown as SEQ ID No.1.The sequence for including signal peptide (underscore) of BP17
Row are shown as SEQ ID No.2.
SEQ ID NO:1:
NDTPASGYQVEKVVILSRHGVRAPTKMTQTMRDVTPNTWPEWPVKLGYITPRGEHLISLMGGFYRQKFQ
QQGILSQGSCPTPNSIYVWTDVAQRTLKTGEAFLAGLAPQCGLTIHHQQNLEKADPLFHPVKAGICSMDKTQVQQAV
EKEAQTPIDNLNQHYIPSLALMNTTLNFSKSPWCQKHSADKSCDLGLSMPSKLSIKDNGNEVSLDGAIGLSSTLAEI
FLLEYAQGMPQAAWGNIHSEQEWALLLKLHNVYFDLMERTPYIARHKGTPLLQAISNALNPNATESKLPDISPDNKI
LFIAGHDTNIANIAGMLNMRWTLPGQPDNTPPGGALVFERLADKSGKQYVSVSMVYQTLEQLRSQTPLSLNQPAGSV
QLKIPGCNDQTAEGYCPLSTFTRVVSQSVEPGCQLQ
SEQ ID NO:2:
MTISAFNRKKLTLHPGLFVALSAIFSLGSTAYANDTPASGYQVEKVVILSRHGVRAPTKMTQTMRDVTP
NTWPEWPVKLGYITPRGEHLISLMGGFYRQKFQQQGILSQGSCPTPNSIYVWTDVAQRTLKTGEAFLAGLAPQCGLT
IHHQQNLEKADPLFHPVKAGICSMDKTQVQQAVEKEAQTPIDNLNQHYIPSLALMNTTLNFSKSPWCQKHSADKSCD
LGLSMPSKLSIKDNGNEVSLDGAIGLSSTLAEIFLLEYAQGMPQAAWGNIHSEQEWALLLKLHNVYFDLMERTPYIA
RHKGTPLLQAISNALNPNATESKLPDISPDNKILFIAGHDTNIANIAGMLNMRWTLPGQPDNTPPGGALVFERLADK
SGKQYVSVSMVYQTLEQLRSQTPLSLNQPAGSVQLKIPGCNDQTAEGYCPLSTFTRVVSQSVEPGCQLQ
In one embodiment, phytase is AxtraPHYTMPhytase.
AxtraPHYTMPhytase is referred to herein as BP17 phytases.
In one embodiment, phytase can come from Hafnia, such as from honeycomb Hough Buddhist nun
The phytase of bacterium (Hafnia alvei), the phytase as taught in US2008263688, this is with reference to text
It offers and is hereby incorporated by reference.
In one embodiment, phytase can come from aspergillus, such as the inositol six from aspergillus oryzae
Phosphatase.
In one embodiment, phytase can come from Penicillium, such as the inositol from penicillium funiculosum
Six-phosphatase.
Unless the context clearly dictates otherwise, term " phytase " can be a kind of phytase or inositol six
The combination of phosphatase.
Preferably, phytase is with about 1500FTU/kg to about 20000FTU/kg feeds, suitably about 1500FTU/
Kg to about 10000FTU/kg feeds, suitably about 1500FTU/kg feeds to about 5000FTU/kg feeds, suitably about
1500FTU/kg feeds are to about 3000FTU/kg feeds, more preferably from about 2000FTU/kg feeds to about 20000FTU/kg feeds, suitable
Preferably about 2000FTU/kg feeds to about 10000FTU/kg feeds, suitably about 2000FTU/kg feeds to about 5000FTU/kg
The range of feed, suitably about 2000FTU/kg feeds to about 3500FTU/kg feeds is present in feed.
In one embodiment, phytase is by more than about 1500FTU/kg feeds, be suitably more than about
2000FTU/kg feeds are suitably present in feed more than about 3000FTU/kg feeds.
In one embodiment, phytase by less than about 15000FTU/kg feeds, suitably less than about
12000FTU/kg feeds are present in feed.
In one embodiment, phytase is deposited with the range of about 1500FTU/kg to about 5000FTU/kg feeds
It is in feed.
In one embodiment, phytase is deposited with the range of about 2000FTU/kg to about 5000FTU/kg feeds
It is in feed.
In preferred embodiments, phytase is deposited with the range of about 1500FTU/kg to about 3000FTU/kg feeds
It is in feed.
In a more preferred embodiment, phytase is with about 2000FTU/kg to the model of about 3000FTU/kg feeds
It encloses and is present in feed.
In one embodiment, phytase can be by existing below in feed addictive composition:
A. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 50g/ tonnes of (MT) feeds
When, by about 30,000FTU/g compositions or more;
B. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 75g/ tonnes of (MT) feeds
When, by about 20,000FTU/g compositions or more;
C. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 100g/ tonnes of (MT) feeds
When, by about 15,000FTU/g compositions or more;
D. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 100g/ tonnes of (MT) feeds
When, by about 15,000FTU/g compositions or more;
E. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 150g/ tonnes of (MT) feeds
When, by about 10,000FTU/g compositions or more;
F. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 200g/ tonnes of (MT) feeds
When, by about 7,500FTU/g compositions or more;
G. the composition in adding to (such as dosage of manufacturer's recommended) feed is equal to or more than 300g/ tonnes of (MT) feeds
When, by about 5,000FTU/g compositions or more.
Expediently, when phytase is present in dosage given above in feed addictive composition, directly
Microorganism is fed with from 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:The range of 1FTU enzymes, suitably with from
3.8x103CFU DFM:1FTU enzymes are to 2.0x105CFU:The range of 1FTU enzymes is present in feed addictive composition.
It should be understood that as used herein, 1FTU (phytase unit) is defined as in 2009 phytases of ISO
It measures under the reaction condition defined in (standard test for measuring phytase activity), from substrate in one minute
The enzyme amount needed for 1 μm of ol inorganic orthophosphate is discharged, and 1FTU can be found in international standard ISO/DIS 30024:1-17,2009.
In one embodiment, expediently, being classified to enzyme using above-mentioned E.C. classification, and E.C. classification instructions
It is teaching herein for measuring test in the measurement of 1FTU when there is the active enzyme.
Advantage
The interaction of DFM and enzyme is complicated, and is not intended to be limited to theory, very it is surprising that we
It can be seen that improvement of the individual to the resistance of necrotic enteritis.Before making the present invention, not yet instructed for the specific purposes DFM with
The specific combination of high phytase (for example, as taught herein).
In addition or alternatively, for animal shows (such as feed conversion rate), add more than by 1500FTU/kg feeds
When entering phytase, the combination of DFM (such as antipathogen DFM) and phytase, which exists, to act synergistically.Independent
When supplementing phytase, there is the raising (i.e. the reduction of FCR) of performance under 500 and 1500FTU/kg feeds, in inositol
There are the reduction of performance (raisings of FCR) when six-phosphatase dosage is more than about 1500FTU/kg feeds.This is in necrotic enteritis
It is especially true under conditions of attack.
But when combining DFM with phytase more than 1500FTU/kg feeds, and phytic acid is only used
Enzymatic treatment is compared, and there are consistent numerical value to increase (i.e. the reduction of FCR) for performance.In 3000FTU/kg feeds and 10,000FTU/kg
Between the level of feed, there are the reductions of big numerical value, lead to FCR minimum in all processing groups.Astoundingly, DFM is (especially
Antipathogen DFM) with more than 1500FTU/kg feeds phytase combination generation synergistic combination.
It is one of the advantages of the invention that DFM (such as antipathogen DFM) and the combination of high dose phytase are aobvious
Writing improves the effect of phytase improves animal performance and/or phosphorus reservation in individual.
Another advantage of the present invention is that DFM (such as antipathogen DFM) and the combination of high dose phytase change
The phosphorus (such as diet phosphorus) being apt in individual absorbs and retains.This compound action is entirely unexpected.
It is one of the advantages of the invention that the feed addictive composition of the present invention can be to avoid the negative of necrotic enteritis
The resistance for acting on or can be used for improving individual to necrotic enteritis.
Be not intended to be limited to theory, phytic acid enzymatic phytate (phosphorus in cereal and beans it is main
Storage form) it is sequentially hydrolyzed into the lower myo-inositol derivative of phosphorylation degree, while discharging inorganic phosphate.Phytic acid
The hydrolysis of salt, which causes to lose the endogenous of the amino acid of enteric cavity, to be reduced.Endogenous Amino Acids loss in intestines, which is reduced, reduces use
In the availability of the nitrogen of bacterial growth, this contributes to the activity of DFM inhibition C.perfringens and other pathogenic bacteria.
It is not intended to be limited to theory, phytase is added and six phosphate of hydrolysis of inositol can lead to small intestine (12
Duodenum 12, jejenum and/or ileum) pH improve.Phytase can also actually increase species Escherichia coli and aerogenesis
The amount of bacteria of capsular clostridium.This can be related to higher pH.Present invention has found that being added with high dose phytase
DFM (especially antipathogen DFM) can offset the increase of pathogenic bacteria.
High dose phytase increases the hydrolysis of six phosphoric acid of animal intestinal tract mysoinositol, can to improve phosphorus, calcium,
Energy, protein and other nutrients digestibility and animal may be showed advantageous.But astoundingly, the present inventor
It has been found that there is clinical or subclinical enteropathy attack (such as the necrotic enteritis in broiler chicken, often in commercial animal production
Occur) when, the phytase of high dose cannot reach the potential improvement to Nutrient digestibility and animal performance.Passing through will
High dose phytase is combined with antipathogen DFM, surprisingly, it was found that even if in six phosphorus of very high inositol
Sour enzyme level (such as 10,000FTU/kg feeds), animal performance also further enhance.
Combination and/or DFM with DFM and standard (low) phytic acid enzyme dosage are individually and/or enzyme (or even high dose flesh
Alcohol six-phosphatase) individually to compare, the combination of high dose phytase and DFM, which astoundingly provide, reduces pathogen
And/or the battalion in necrotic enteritis and/or feed conversion rate, and/or weight gain and/or individual performance and/or reduction muck
Support significantly improving for object excretion.
The preparation of DFM and enzyme
DFM and one or more enzymes can be prepared in any suitable manner, with ensure preparation include living DFM and it is a kind of or
Multiple active enzymes.
In one embodiment, DFM and one or more enzymes can be formulated as liquid, dry powder or particle.
Dry powder or particle can by means well known by persons skilled in the art, for example, in top-jet-type fluid bed coater,
In Wurster type bottom spraying types fluid bed (buttom spray Wurster) or pass through rotary drum granulation (such as high shear system
Grain), squeeze out, pan coating or prepared in micro- Component mixer.
For some embodiments, (such as being encapsulated) DFM and/or enzyme can be coated with.Expediently, DFM and enzyme can be formulated in
In same coating or it is encapsulated in same capsule.Alternatively, one or more enzymes can be formulated in a coating or is encapsulated in
In one capsule, and can be separately formulated in coating by DFM and one or more enzymes.In some embodiments, if such as
DFM can generate endospore, then can provide DFM without any coating.In these cases, can simply by
DFM endospores mix with one or more enzymes.In the latter case, (such as being encapsulated) one or more enzymes can be coated with.
In one embodiment, coating protects one or more enzymes from heat affecting and can be considered anti-thermit powder.
In one embodiment, feed addictive composition is configured to dry powder or particle, such as WO2007/044968
Described in (being known as TPT particles) or WO1997/016076 or WO1992/012645 (each patent is hereby incorporated by reference).
In one embodiment, feed addictive composition can be configured to the particle for fodder compound, wrapped
It includes:Core;Activating agent;With at least one coating, after one or more conditions in following, the activating agent of particle retains
At least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity:A) feed pill method, b) steam heating
Feed preprocess method, c) storage, d) as in the mixture without pill ingredient storage and e) conduct include at least one
The feed base mix of kind compound chosen from the followings or the ingredient storage in feed premix:Trace minerals, organic acid,
The compound of reduced sugar, vitamin, choline chloride and generation acidity or alkaline feed basic mixture or feed premix.
About particle, at least one coating may include at least moisture hydrating material of 55w/w% for constituting particle;And/or
At least one coating may include two coatings.Two coatings can be moisture hydration coating and moisture barrier coating.At some
In embodiment, moisture hydration coating can be the 25w/w% of particle between 60w/w% and moisture barrier coating can be particle
2w/w% between 15w/w%.Moisture hydration coating can be selected from inorganic salts, sucrose, starch and maltodextrin and moisture screen
Barrier coating can be selected from polymer, natural gum, whey and starch.
Particle can be used feed pill method prepare and feed preprocess method can be carried out between 70 DEG C to 95 DEG C to
Between most minutes, such as 85 DEG C to 95 DEG C.
In one embodiment, feed addictive composition can be configured to the particle for animal feed comprising:
Core;Activating agent, the activating agent of particle after storage and particle be ingredient steam heat pill method after retain to
Few 80% activity;Moisture barrier coating;Moisture is hydrated coating, is at least 25w/w% of particle, and pill method is heated in steam
Before, which has the water activity less than 0.5.
It can be inorganic salts that particle, which can have the moisture barrier coating selected from polymer and natural gum and moisture hydrating material,.Water
Point hydration coating can be particle 25w/w% between 45w/w% and moisture barrier coating can be the 2w/w% of particle extremely
Between 10w/w%.
Steam heating pill method can be used to prepare for particle, and this method can be carried out within several points between 85 DEG C to 95 DEG C
Clock.
In some embodiments, diluent (such as starch powder, lime stone or the like) can be used to dilute DFM (examples
Such as DFM endospores).
In one embodiment, composition is in edible liquid preparation, it is preferable that this liquid edible object
Containing one or more in following:Buffer, salt, sorbierite and/or glycerine.
In another embodiment, can by by one or more enzymes apply (such as spraying) in carrier substrate (such as
The wheat pulverized) come up formula feed compositions of additives.
In one embodiment, feed addictive composition of the invention can be formulated as pre-composition.It is only used as example, it should
Pre-composition may include one or more feed ingredients, such as one or more minerals and/or one or more vitamins.
In one embodiment, it can will be selected from such as at least one for the DFM of the present invention and/or one or more enzymes
At least one of lower physiologically acceptable carrier is prepared together:Maltodextrin, lime stone (calcium carbonate), ring paste
Essence, wheat or wheat component, sucrose, starch, Na2SO4, talcum powder, PVA, sorbierite, benzoate, sorbate, glycerine, sugarcane
Sugar, propylene glycol, 1,3- propylene glycol, glucose, p-hydroxybenzoate, sodium chloride, citrate, acetate, phosphate, calcium,
Metabisulfite, formates and its mixture.
Packaging
In one embodiment, the feed addictive composition to the present invention and/or pre-composition and/or feed wrap
Dress.
In a preferred embodiment, by feed addictive composition and/or pre-composition and/or feed package in bag
In (such as paper bag).
In alternative embodiment, feed addictive composition and/or pre-composition and/or feed can be sealed in container
In.The container of any suitable can be used.
Feed
The feed addictive composition of the present invention can be used as feed or be used to prepare feed.
Term " feed (feed) " is used with " feed (feedstuff) " herein as synonym.
Depending on purposes and/or application model and/or method of application, feed can be in solution form or be in solid form.
When as (or being used to prepare) feed (such as functional feed), the present composition can in following substance
One or more combined uses:Nutritionally acceptable carriers, nutritionally acceptable diluent, nutritionally acceptable figuration
Agent, nutritionally acceptable adjuvant, neutraceutical active ingredients.
In preferred embodiments, the feed addictive composition of the present invention is mixed with feed ingredient to form feed.
The term as used herein " feed ingredient " means all or part of feed.The part of feed can refer to the one of feed
More than one (such as 2 kinds or 3 kinds or 4 kinds) ingredients of kind ingredient or feed.In one embodiment, term " feed ingredient "
Cover pre-composition or premix ingredients.
Preferably, feed can be forage (fodder) or its pre-composition, mixed feed or its pre-composition.In an embodiment party
In case, can the feed addictive composition of the present invention be mixed or be mixed to compound with mixed feed, mixed feed component
The pre-composition of feed is mixed into the pre-composition of forage, forage component or forage.
The term as used herein forage means the arbitrary food for being supplied to animal (and non-animal oneself must look for food).Forage
Cover cut plant.
Term forage includes feed, oil and mixed ration and germinated ceral and the beans of ensilage, compacting and pill.
Forage can be obtained from one or more in plant chosen from the followings:Barley, rape (Canola), corn (beautiful another name for Sichuan Province
Broomcorn millet), grain, oat, sorghum, soybean, wheat and beans.
Term " mixed feed " means the commercial feed of coarse powder, pellet, nut, cake or debris form.Mixed feed can be by
Plurality of raw materials and additive are blended.These blends are prepared according to the specific requirements of target animal.
Mixed feed can be to provide the complete feeding-stuffs of all daily needed nutrients, provide daily ration (ration) (albumen
Matter, energy) a part concentrate or the replenishers of additional micronutrient (such as minerals and vitamins) are only provided.
It is feed grain for the main component in mixed feed comprising corn and soybean, sorghum, wheat, oat and big
Wheat.
Expediently, the composition that the pre-composition mentioned by this paper can be made of micro constitutent, which is example
As vitamin, minerals, chemical preservative, antibiotic, tunning and other must ingredient.Pre-composition is generally suitable in altogether
The composition being mixed into business daily ration.
The arbitrary feed of the present invention may include one or more Feed Materials chosen from the followings:A) cereal, such as granule paddy
Object (such as wheat, barley, rye, oat and combinations thereof) and/or big grain cereal such as maize or sorghum;B) pair from cereal
Product, such as corn protein powder, wet cake (wet cake for being based especially on corn), distiller's dried grain (DDG) (are based especially on the dry of corn
Vinasse (cDDG)), distiller's dried grain soluble matter (DDGS) (the distiller's dried grain soluble matter (cDDGS) for being based especially on corn), wheat bran, wheat
Coarse powder, wheat wheat-middlings, rice bran, rice husk, oat shell, palm kernel and citrus pulp;C) it is obtained from the protein in following source:As soybean,
Sunflower, peanut, lupin, pea, broad bean, cotton, Canola, fish meal, dry plasma protein, meat and bone meal, potato egg
In vain, whey, copra, sesame;D) it is obtained from the oil & fat in plant and animal source;E) minerals and vitamins.
The feed of the present invention contains the corn of at least 10wt%, at least 20wt%, at least 30wt% or at least 50wt%
With soy meal or corn and full-fat bean or wheat flour or sunflower powder.
The feed of the present invention can include the corn DDGS between about 0% to about 40%.If feed includes arbitrary corn
DDGS, then it can include the corn DDGS between about 5% to about 40%.For poultry, when there are corn DDGS, feed is flat
It can include the corn DDGS between about 7% to about 15%.For pig, when there are corn DDGS, feed can averagely wrap
Containing 5% to 40% corn DDGS.
The feed of the present invention can be comprising corn as single cereal, in this case, and feed can include about 35%
To about 80% corn.
In the present invention, one or more during feed can be as follows:Mixed feed and pre-composition comprising pellet,
Nut or (domestic animal use) cake;Crops or crop residues:Corn and soybean, sorghum, oat, barley, copra, husk,
Sugar beet waste products;Fish meal;Meat and bone meal;Molasses;Oil cake and filter press cake;Oligosaccharide;The forage plant of preservation:Ensilage;Sea
Algae;Seed and cereal are entire or by the preparations such as rolling or grinding;Germinated ceral and beans;Yeast extract.
In some embodiments, the term feed in the present invention is also covered by pet food.Pet food is intended to by doting on
The edible plant of object or animal material, such as dog food or cat foods.Pet food (such as dog and cat foods) can be drying
Form (grate foods as being used for dog) or wet canned form.Cat foods can contain amino acid taurine.
In some embodiments, the term feed in the present invention is also covered by fish food.Fish food, which usually contains, makes cultivation
Fish is kept fit required main nutrient, trace element and vitamin.Fish food can be the form of small pieces, pellet or piece.
The form (some of which rapid subsidence) for being pressed into pellet is frequently used for larger fish or species are raised at bottom.Some fish foods also contain
The additive of such as bata-carotene or sex hormone etc, manually to enhance the color of ornamental value fish.
In some embodiments, the term feed in the present invention is also covered by birdseed product.Birdseed product include being used for bird feeder
In and the food for feeding pet bird.In general, birdseed product are made of a variety of seeds, but it can also cover leaf fat (ox or suet
Fat).
The term as used herein " contact " refers to that the composition of the present invention is directly or indirectly applied to product (such as to raise
Material) in.The example of workable applying method includes but not limited to:Production is handled in the material comprising feed addictive composition
Product, by the way that feed addictive composition and product mix are directly applied, feed addictive composition is sprayed into product table
It is immersed in the preparation of feed addictive composition on face or by product.
In one embodiment, it is preferred to which the feed addictive composition of the present invention is mixed with product (such as feed).
Alternatively, it may include feed addictive composition in the lotion or primitive component of feed.
For some application, it is important that make composition on the product surface for waiting for influence/processing can with or can be used for waiting for
The product surface of influence/processing.It is one or more in following advantageous feature that this enables composition to assign:Show benefit.
Can apply the present invention feed addictive composition so that product (such as primitive component of feed or feed) spread,
It is coated with and/or is impregnated with the DFM of controlled quentity controlled variable and one or more enzymes.
DFM and one or more enzymes can be used simultaneously (for example, when they are mixed or even passing through not at them
When being delivered with approach) or sequentially use (for example, they can be delivered by different approaches).In one embodiment, it is preferred to ground,
Apply DFM and one or more enzymes simultaneously.Preferably, DFM is mixed with one or more enzymes, they is then delivered to feed
Or the primitive component of feed.
The present invention feed addictive composition in DFM can be suitable concentration addition --- such as final feed product
In concentration can provide about 2 × 105CFU to about 2 × 1011Between CFU, suitably between about 2 × 106CFU to about 1 × 1010CFU
Between, suitably between about 3.75 × 107CFU to about 1 × 1010Daily dose between CFU.
Preferably, feed addictive composition of the invention will be to a maximum of about of 70 DEG C, a maximum of about of 85 DEG C or a maximum of about of 95 DEG C
Heat treatment be heat-staple.Heat treatment can carry out most about 1 minute, most about 5 minutes, most about 10 minutes, most about
30 minutes, most about 60 minutes.Term is heat-staple to be meant to exist in additive before being heated to assigned temperature/and it is active
In enzyme component and/or DFM at least about 75% after cooling to room temperature there are still/it is active.Preferably, it is being heated to specified temperature
Exist in additive before degree and active enzyme component and/or DFM at least about 80% after cooling to room temperature there are still
And it is active.
In especially preferred embodiment, feed addictive composition is homogenized to generate powder.
In alternative preferred embodiment, feed addictive composition is configured to as described in WO2007/044968
Particle (be referred to as TPT particles), which is hereby incorporated by reference.
In another preferred embodiment of the present, when feed addictive composition is configured to particle, these particles include to apply
Hydrated barrier salt of the cloth on protein core.The advantage of this salt coating is to improve heat resistance, improve storage stability and guarantor
Protect the influence of other feed addictives to enzyme and/or DFM from script with detrimental effect.
Preferably, the salt for being used for salt coating has the water activity or constant wet more than 60% for being more than 0.25 at 20 DEG C
Degree.
Preferably, salt coating includes Na2SO4。
The method for preparing feed addictive composition may also include another step of powder pill.Powder can be with ability
Other components known to domain are mixed.Powder or mixture comprising powder can be forced by mold, and by obtained material
Item is cut into the suitable pellet of variable-length.
Optionally, pill step may include the steam treatment carried out before forming pellet or conditioning stage.Can will include
The mixture of powder is placed in regulation machine, such as the mixing machine that carrying vapour sprays.Mixture is heated to specifying in regulation machine
Temperature, such as from 60 DEG C to 100 DEG C, typical temperature can be 70 DEG C, 80 DEG C, 85 DEG C, 90 DEG C or 95 DEG C.Residence time is indefinite, can
From the several seconds to several minutes or even a few hours.Such as 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 points
Clock, 30 minutes and 1 hour.
It should be appreciated that the feed addictive composition of the present invention is suitable for being added in any suitable Feed Material.
The term as used herein Feed Material refers to the basal feed material waited for by animal edible.It should also be understood that this may include
For example, at least one or more crude cereal and/or processed plant and/or animal material, such as soy meal or bone
Powder.
The term as used herein " feed " refers to being added to the feed material of one or more feed addictive compositions
Material.
Technical staff is, it will be recognized that different animals needs different feeds or even same animal that can also need not
Same feed, this depends on the purpose for raising the animal.
Preferably, feed may include such Feed Material, it includes maize or corn, wheat, barley, triticale,
Rye, rice, cassava, sorghum and/or arbitrary by-product, and the ingredient rich in protein, such as soy meal, ground oil seeds, Kano
Draw powder, cotton seed meal, sunflower seed powder, animal byproducts powder and its mixture.It is highly preferred that feed may include animal tallow and/or
Vegetable oil.
Optionally, feed can also contain additional minerals (such as calcium) and/or additional vitamin.
Preferably, feed is corn soybean powder mixture.
In one embodiment, it is preferred to ground, feed is not pet food.
On the other hand, the method for producing feed is provided.Feed usually produces in feed metal, first in grinding machine
Raw material is first ground into suitable granularity, is then mixed with additive appropriate.Feed can then be used as thickener or pellet system
It is standby;The latter, which is usually directed to, to be raised the temperature to target level and feed is then made to pass through mold with the pellet that generates specific dimensions
Method.Pellet is set to cool down.It then, can adding liquid additive such as fat and enzyme.The preparation of feed may also refer to additional step,
Its extrusion or expansion before being included in pill --- it is carried out especially by the appropriate technology that may include at least using steam.
Feed can be for nonruminant such as poultry (such as broiler chicken, laying hen, Breeder hens, turkey, duck, goose, aquatic bird), pig
The feed of (all age categories), pet (such as dog, cat) or fish, preferably feed are used for poultry.
In one embodiment, feed is not intended to laying hen.
It is only used as example, the % that the feed for chicken (such as broiler chicken) can provide in such as according to the form below includes listed in following table
It is one or more in ingredient:
Ingredient | Opened guideway (%) | Fattening material (%) |
Maize | 46.2 | 46.7 |
Sizing | 6.7 | 10.0 |
Maize DDGS | 7.0 | 7.0 |
Soy meal 48%CP | 32.8 | 26.2 |
Animal/vegetable fat blend | 3.0 | 5.8 |
L-lysine HCl | 0.3 | 0.3 |
DL- methionines | 0.3 | 0.3 |
L-threonine | 0.1 | 0.1 |
Salt | 0.3 | 0.4 |
Lime stone | 1.1 | 1.1 |
Dicalcium Phosphate | 1.2 | 1.2 |
Poultry vitamin and trace mineral | 0.3 | 0.3 |
It is only used as example, the diet specification for chicken (such as broiler chicken) can be as shown in following table:
Diet specification | ||
Crude protein (%) | 23.00 | 20.40 |
Poultry metabolic energy (kcal/kg) | 2950 | 3100 |
Calcium (%) | 0.85 | 0.85 |
Available phosphorus (%) | 0.38 | 0.38 |
Sodium (%) | 0.18 | 0.19 |
Digestible lysine (%) | 1.21 | 1.07 |
Digestible methionine (%) | 0.62 | 0.57 |
Digestible methionine+cysteine (%) | 0.86 | 0.78 |
Digestible threonine (%) | 0.76 | 0.68 |
It is only used as example, the feed for laying hen can be made of one or more in ingredients listed in following table, such as with
The % provided in following table:
Ingredient | Laying period (%) |
Maize | 10.0 |
Wheat | 53.6 |
Maize DDGS | 5.0 |
Soy meal 48%CP | 14.9 |
Sizing | 3.0 |
Soybean oil | 1.8 |
L-lysine HCl | 0.2 |
DL- methionines | 0.2 |
L-threonine | 0.1 |
Salt | 0.3 |
Dicalcium Phosphate | 1.6 |
Lime stone | 8.9 |
Poultry vitamin and trace mineral | 0.6 |
It is only used as example, the diet specification for laying hen can be as shown in following table:
Diet specification | |
Crude protein (%) | 16.10 |
Poultry metabolic energy (kcal/kg) | 2700 |
Lysine (%) | 0.85 |
Methionine (%) | 0.42 |
Methionine+cysteine (%) | 0.71 |
Threonine (%) | 0.60 |
Calcium (%) | 3.85 |
Available phosphorus (%) | 0.42 |
Sodium (%) | 0.16 |
It is only used as example, the feed for turkey can be made of one or more in ingredients listed in following table, such as with
The % provided in following table:
It is only used as example, the diet specification for turkey can be as shown in following table:
Diet specification | ||||
Crude protein (%) | 29.35 | 26.37 | 22.93 | 20.00 |
Poultry metabolic energy (kcal/kg) | 2.850 | 2.900 | 2.950 | 3.001 |
Calcium (%) | 1.43 | 1.33 | 1.22 | 1.02 |
Available phosphorus (%) | 0.80 | 0.71 | 0.65 | 0.53 |
Sodium (%) | 0.16 | 0.17 | 0.17 | 0.17 |
Digestible lysine (%) | 1.77 | 1.53 | 1.27 | 1.04 |
Digestible methionine (%) | 0.79 | 0.71 | 0.62 | 0.48 |
Digestible methionine+cysteine (%) | 1.12 | 1.02 | 0.90 | 0.74 |
Digestible threonine (%) | 1.03 | 0.89 | 0.73 | 0.59 |
It is only used as example, the feed for piglet can be made of one or more in ingredients listed in following table, such as with
The % provided in following table:
Ingredient | Stage 1 (%) | Stage 2 (%) |
Maize | 20.0 | 7.0 |
Wheat | 25.9 | 46.6 |
Rye | 4.0 | 10.0 |
Sizing | 4.0 | 4.0 |
Maize DDGS | 6.0 | 8.0 |
Soy meal 48%CP | 25.7 | 19.9 |
Dry whey | 10.0 | 0.0 |
Soybean oil | 1.0 | 0.7 |
L-lysine HCl | 0.4 | 0.5 |
DL- methionines | 0.2 | 0.2 |
L-threonine | 0.1 | 0.2 |
L-Trp | 0.03 | 0.04 |
Lime stone | 0.6 | 0.7 |
Dicalcium Phosphate | 1.6 | 1.6 |
Pig vitamin and trace mineral | 0.2 | 0.2 |
Salt | 0.2 | 0.4 |
It is only used as example, the diet specification for piglet can be as shown in following table:
Diet specification | ||
Crude protein (%) | 21.50 | 20.00 |
Pig digestible energy (kcal/kg) | 3380 | 3320 |
Pig net energy (kcal/kg) | 2270 | 2230 |
Calcium (%) | 0.80 | 0.75 |
Digestible phosphorus (%) | 0.40 | 0.35 |
Sodium (%) | 0.20 | 0.20 |
Digestible lysine (%) | 1.23 | 1.14 |
Digestible methionine (%) | 0.49 | 0.44 |
Digestible methionine+cysteine (%) | 0.74 | 0.68 |
Digestible threonine (%) | 0.80 | 0.74 |
It is only used as example, the feed for grower pigs/fattening pig can be by one or more groups in ingredients listed in following table
At, such as the % that is provided in following table:
Ingredient | Growth material/fattening material (%) |
Maize | 27.5 |
Soy meal 48%CP | 15.4 |
Maize DDGS | 20.0 |
Wheat bran | 11.1 |
Rice bran | 12.0 |
Canola seed powder | 10.0 |
Lime stone | 1.6 |
Dicalcium Phosphate | 0.01 |
Salt | 0.4 |
Pig vitamin and trace mineral | 0.3 |
Lysine-HCl | 0.2 |
Vegetable oil | 0.5 |
It is only used as example, the diet specification for grower pigs/fattening pig can be as shown in following table:
Diet specification | |
Crude protein (%) | 22.60 |
Pig metabolic energy (kcal/kg) | 3030 |
Calcium (%) | 0.75 |
Available phosphorus (%) | 0.29 |
Digestible lysine (%) | 1.01 |
Digestible methionine+cysteine (%) | 0.73 |
Digestible threonine (%) | 0.66 |
Form
The feed addictive composition and other components and/or can be with any suitable shape comprising their feed of the present invention
Formula uses.
The feed addictive composition of the present invention can be used with solid or liquid preparation or its alterative version.Solid pharmaceutical preparation
Example includes powder, paste, bolus, capsule, pill, tablet, powders and granules, can be wettable, spraying
It is dry or freeze-drying.The example of liquid preparation is including but not limited to aqueous, organic or aqueous-organic solutions agent, is suspended
Agent and emulsion.
In some applications, can the DFM of the present invention or feed addictive composition be mixed or is applied to feed and drunk
In water.In one embodiment, the dosage range including in water inlet is about 1 × 103CFU/ animals/day is to about 1 × 1010CFU/
Animal/day, more preferably from about 1 × 107CFU/ animals/day.
The example of suitable form include it is following in it is one or more:Powder, paste, bolus, pellet, tablet, ball
Agent, capsule, vaginal suppository, solution or suspension can contain corrigent or colorant, for discharging at once, postponing to release
It puts, adjust release, sustained release, pulse release or controlled release application.
For example, if the composition of the present invention is used with solid (such as pellet form), can also contain as follows
In it is one or more:Excipient, such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium monohydrogen phosphate and glycine;It collapses
Solve agent, such as starch (preferably corn, potato or tapioca), sodium starch glycollate, croscarmellose sodium and
Certain composition silicates;Granulation binders, such as polyvinylpyrrolidone, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl are fine
Dimension plain (HPC), sucrose, gelatin and Arabic gum;Lubricant, such as magnesium stearate, stearic acid, Gan You behenic acids esters and talcum
Powder.
The example for being used to prepare the nutritionally acceptable carriers of these forms includes (for example) water, salting liquid, alcohol, organic
Silicon (silicone), wax, mineral jelly, vegetable oil, polyethylene glycol, propylene glycol, liposome, sugar, gelatin, lactose, amylose,
Magnesium stearate, talcum powder, surfactant, silicic acid, viscous paraffin, perfume oil, fatty mono glyceride and fatty acid glycerine two
Ester, petroleum ether (petroethral) aliphatic ester, methylol-cellulose, polyvinylpyrrolidone etc..
Preferred excipient for these forms includes lactose (lactose), starch, cellulose, lactose (milk
) or high molecular weight polyethylene glycol sugar.
For aqueous suspension and/or elixir, can by composition and various sweeteners or the corrigent of the present invention,
Color substance or dyestuff, with emulsifier and/or suspending agent and with diluent (such as water, propylene glycol and glycerine) and their group
Conjunction is combined.
Unwetted whey is commonly used as the carrier for DFM (especially bacterium DFM) and is the good medium for causing growth.
Paste containing bacterium DFM can be congealed into vegetable oil and inertia glue together with assignment system.
Fungal product can be formulated together with the cereal byproduct as carrier.
In one embodiment, it is preferred to ground, feed addictive composition according to the present invention is not microparticulate systems (example
Microparticulate systems as taught in WO2005/123034) form.
It gives
The DFM and/or feed addictive composition of the present invention may be configured to once give or designed in terms of daily
Feeding.
The optimised quantity for being ready to use in the composition (and each component therein) in present invention combination will be depending on pending
Product and/or the method and/or its desired use for so that product is contacted with composition.
Amount for DFM and one or more enzymes in composition, which should be, to be enough effective for and is enough to keep to have enough
Effectiveness is in the amount of the performance for the animal for improving feed product of the feeding containing the composition.
The time span of validity should extend up to at least with the product (such as feed addictive composition or contain
Its feed) time.
In the range of the ratio of DFM and enzyme can be provided below in feed:
DFM:Phytase (CFU/FTU):From 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:1FTU enzymes
In the range of;It is preferred that from 3.8x103CFU DFM:1FTU enzymes are to 2.0x105CFU:In the range of 1FTU enzymes.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 1500FTU/kg feeds;With
At least 7.5x104CFU/g to 3.0x105The Envivo Pro (DFM) of CFU/g feeds.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 2000FTU/kg feeds;With
At least 7.5x104CFU/g to 3.0x105The Envivo Pro (DFM) of CFU/g feeds.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 3000FTU/kg feeds;With
At least 7.5x104CFU/g to 3.0x105The Envivo Pro (DFM) of CFU/g feeds.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 1500FTU/kg feeds;With
At least 5x104CFU/g to 1x107The DFM of CFU/g feeds.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 2000FTU/kg feeds;With
At least 5x104CFU/g to 1x107The DFM of CFU/g feeds.
In one embodiment, it is preferred to ground, feed includes following:
(at least) phytase of 3000FTU/kg feeds;With
At least 5x104CFU/g to 1x107The DFM of CFU/g feeds.
In one embodiment, feed includes following:
In preferred embodiments, feed addictive composition is as follows feed is added comprising enough enzyme and DFM:
(at least) phytase of 1500FTU/kg (such as (at least) 2000FTU/kg) feed;With
75,000CFU/g to 150,000CFU/g feeds Envivo Pro (DFM).
In preferred embodiments, feed addictive composition is as follows feed is added comprising enough enzyme and DFM:
(at least) phytase of 1500FTU/kg (such as (at least) 2000FTU/kg) feed;With
37,500CFU/g to 75,000CFU/g feeds Envivo Pro (DFM).
With the combination of other compositions
For in the present invention DFM and one or more enzymes can be applied in combination with other compositions.Therefore, the invention further relates to
Combination.The combination of DFM and phytase can be described as " feed addictive composition of the invention " herein.
The combination of the present invention is comprising the feed addictive composition (or one or more component) of the present invention and suitable for dynamic
Object is edible and another ingredient of medicine or physiological benefit can be provided for eater.
In one embodiment, it is preferred to ground, it is not other enzymes or other DFM to be somebody's turn to do " another seam part ".
These ingredients can be probiotics.Probiotics are typically the non-digestion degraded or absorbed not in upper digestive tract
Property carbohydrate (oligosaccharide or polysaccharide) or sugar alcohol.It is neutralized for commercial product and includes for the known probiotics of the present invention
Inulin (oligofructose or FOS) and oligomeric trans-galacto (GOS or TOS).Suitable probiotics include palatinose-oligosaccharides,
It is soyabean oligosaccharides, alginate, xanthans, pectin, locust bean gum (LBG), inulin, guar gum, galactooligosaccharide (GOS), low
Fructooligosaccharides (FOS), nondegradable starch, lactosucrose, lactulose, lactitol, maltitol, maltodextrin, dextrosan
(i.e.), lactitol, lactosucrose, soyabean oligosaccharides, palatinose, oligoisomaltose, glucooligosaccharides sugar and it is oligomeric
Xylose, pectin fragments, dietary fiber, Oligomeric manna sugar.
Dietary fiber may include non-starch polysaccharide (such as arabinoxylan), cellulose and many other plants
Ingredient, such as resistant dextrin, inulin, lignin, wax, chitin, pectin, beta glucan and oligosaccharide.
In one embodiment, the present invention relates to the feed addictive composition of the present invention (or its one or more groups
Point) with the combination of probiotics.In another embodiment, the present invention relates to include DFM and high dose phytase and benefit
The feed addictive composition of the combination (or consisting essentially of or be made from it) of bacterium member.
Probiotics can be with feed addictive composition (or its component) of the invention simultaneously (for example, mixing therewith
Object is delivered simultaneously by identical or different approach) or (such as by identical or different approach) is applied after which.
The present invention combination other compositions include dextrosan (such as) and/or maltodextrin and/or breast
Sugar alcohol.These other compositions can be optionally added in feed addictive composition to assist drying process and help DFM
Survival.
Other examples of other suitable ingredients include it is following in it is one or more:Thickener, gelling agent, emulsifier,
Adhesive, crystal modifier, sweetener (including artificial sweetener), rheology modifier, stabilizer, antioxidant, dyestuff, enzyme,
Carrier, medium, excipient, diluent, lubricant, corrigent, coloring material, suspending agent, disintegrant, granulation binders etc..
These other compositions can be natural.These other ingredients can be prepared by using chemistry and/or zymetology technology.
In a preferred embodiment, the DFM and/or enzyme being used in the present invention can be combined with one or more lipids
It uses.
For example, the DFM and/or enzyme that are used in the present invention can be applied in combination with one or more lipid micelles.Lipid
Protomere can be simple lipid protomere or complex lipids protomere.
Lipid micelles can be the aggregation of the orientation molecule of amphiprotic substance (such as lipid and/or oil).
The term as used herein " thickener or gelling agent " refer to by slow down or prevent particle (immiscible liquid it is small
Drop, air or insoluble solid) it moves and prevents the product detached.Viscosity is caused to increase in individual hydrate molecule, to subtract
When slow separation, thicken.When the molecule connection of hydration formed can trapped particle three-dimensional network, thus make these particles solid
Timing is gelled.
The term as used herein " stabilizer " is defined as keeping product (such as feed product) from over time becoming
The combination of the ingredient or ingredient of change.
The term as used herein " emulsifier " refers to the ingredient (such as feed ingredient) for preventing lotion from detaching.Lotion is two kinds
Unmixing substance, one kind exist with droplet, are contained in another one.Lotion can (wherein droplet or dispersed phase be by oil-in-water
Oil and continuous phase is water) or Water-In-Oil (wherein water becomes dispersed phase and continuous phase is oil) composition.It also can be by using emulsifier
To make foam (it is gas-in-liquid) and suspension (it consolidates suspension for liquid) stablize.
The term as used herein " adhesive " refers to by physically or chemically reacting the combined ingredient (example of product
Such as feed ingredient).For example, during " gelling ", water is absorbed, to provide in conjunction with effect.However, adhesive can absorb other
Liquid (such as oil), to hold it in product.In the background of the invention, adhesive will be commonly used in solid or low water
Point product (such as baked product:Dessert, baked donut, bread etc.) in.
" carrier " or " medium " means suitable for the material using DFM and/or enzyme, and includes known in the art
It anticipates this material, such as arbitrary liquid, gel, solvent, liquid diluent, stabilizer etc., it is nontoxic and not with harmful way
It interacts with any ingredient of composition.
The present invention is provided to prepare the method for feed addictive composition, this method includes by DFM and phytic acid
Enzyme is mixed at least one selected from least one of following physiologically acceptable carrier:Maltodextrin, lime stone
(calcium carbonate), cyclodextrin, wheat or Wheat components, sucrose, starch, Na2SO4, talcum powder, PVA, sorbierite, benzoate, mountain
Pears hydrochlorate, glycerine, sucrose, propylene glycol, 1,3- propylene glycol, glucose, p-hydroxybenzoate, sodium chloride, citrate, acetic acid
Salt, phosphate, calcium, metabisulfite, formates and its mixture.
The example of excipient include it is following in it is one or more:Microcrystalline cellulose and other celluloses, lactose, citric acid
Sodium, calcium carbonate, calcium monohydrogen phosphate, glycine, starch, lactose and high molecular weight polyethylene glycol.
The example of disintegrant include it is following in it is one or more:Starch (preferably corn, potato or tapioca), hydroxyl
Guanidine-acetic acid sodium starch, croscarmellose sodium and certain composition silicates.
The example of granulation binders include it is following in it is one or more:Polyvinylpyrrolidone, hydroxypropyl methyl fiber
Plain (HPMC), hydroxypropyl cellulose (HPC), sucrose, maltose, gelatin and Arabic gum.
The example of lubricant include it is following in it is one or more:Magnesium stearate, stearic acid, Compritol 888 ATO and talcum
Powder.
The example of diluent include it is following in it is one or more:Water, ethyl alcohol, propylene glycol and glycerine and combinations thereof.
Other compositions can be used simultaneously (such as when they are mixed or even when they pass through different approaches
When delivering) or sequentially use (such as they can be delivered by different approaches).
Preferably, when mixing the feed addictive composition of the present invention with another ingredient, DFM remains living.
In one embodiment, it is preferred to ground, feed addictive composition of the invention does not include chromium or Organic Chromium.
Concentrate
Can be concentration form for the DFM in the present invention.In general, these concentrates include the DFM of suitable high concentration.
The content (colony forming unit, CFU) for the living cells that the feed addictive composition of the present invention can have is at least
104CFU/g (includes suitably at least 105CFU/g, such as at least 106CFU/g, for example, at least 107CFU/g, at least 108CFU/g) extremely
About 1010CFU/g (or even about 1011CFU/g or about 1012CFU/g in the range of).
When DFM is concentration form, the content for the living cells that feed addictive composition of the invention can have is extremely
Few 109CFU/g to about 1012CFU/g, preferably at least 1010CFU/g to about 1012In the range of CFU/g.
Powder, granule and the liquid composition dilutable water of concentration form are resuspended in water or other are suitable dilute
It releases in agent (such as growth medium appropriate, such as breast or minerals or vegetable oil), to generate available composition.
Can be prepared according to methods known in the art concentration form the present invention DFM or feed addictive composition or
The combination of the present invention.
In one aspect of the invention, composition catalase or feed in a concentrated form.
The composition of the present invention can be spray-dried or is freeze-dried by methods known in the art.
Prepared with spray drying process particle typical method be related to being dissolved in appropriate solvent solid material (for example,
DFM cultures in fermentation medium).Alternatively, material can be suspended or is emulsifiable in non-solvent to form suspension or breast
Liquid.Can optionally add at this stage other compositions (as discussed above) or such as antimicrobial, stabilizer, dyestuff and
Assist the ingredient of substance of drying process etc.
Then make solution atomization to form the mist of droplet.Droplet immediately enters in hothouse, wherein its contact drying
Gas.Solvent evaporates into dry gas from droplet and cures droplet, to form particle.Then grain is detached from dry gas
Son is simultaneously collected.
Individual
The term as used herein " individual " mean it is to be administered or applied the present invention feed addictive composition or comprising
The animal of the feed of the feed addictive composition of the present invention.
The term as used herein " individual " means animal.
Preferably, individual is mammal, bird, fish or shellfish, including such as domestic animal or performing animal (such as dote on
Object).
In one embodiment, " individual " is domestic animal.
The term as used herein " domestic animal " refers to arbitrary farm-animals.Preferably, domestic animal be it is following in it is one or more:
Ruminant, such as ox (such as milk cow or bull (including calf));Nonruminant, such as poultry (including broiler chicken, chicken and turkey), pig
(including piglet), bird;Aquatic animal, such as fish, without stomach fish, have stomach fish, fresh-water fishes (such as salmon, gadus, trout and carp, such as
Fancy carp), ocean fish (such as jewfish), shellfish (such as shrimp, mussel and scallop), horse (including horse racing), sheep (including lamb).
In another embodiment, " individual " is performing animal or pet or the animal that is maintained in the environment of zoo.
The term as used herein " performing animal or pet or the animal being maintained in the environment of zoo " refers to arbitrary correlation
Animal, including canid (such as dog), felid (such as cat), rodent (such as cavy, rat, mouse), bird,
Fish (including fresh-water fishes and ocean fish) and horse.
In one embodiment, individual can be attacked by enteropathogen.
As example, may exist one or more enteropathogens in individual intestines or alimentary canal.For example, individual intestines or
The one or more enteropathogens that can have by such level in alimentary canal, the level:
I) lead to the loss of the performance of animal;And/or
Ii) it is clinical relevant levels;Or
Iii) it is subclinical levels.
Enteropathogen can be such as C.perfringens.
Performance
" animal performance " used herein by the weightening of feed efficiency and/or animal and/or can pass through feed conversion rate
And/or the digestible energy in the digestibility (such as amino acid digestibility) and/or feed for passing through the nutrients in feed or metabolism
The ability of the negative effect of necrotic enteritis can and/or be avoided by nitrogen reservation and/or by animal and/or is exempted from by individual
Epidemic disease reacts to measure.
Preferably, " animal performance " is measured by the weightening and/or feed conversion rate of feed efficiency and/or animal.
" improved animal performance " means compared with the feed of the feed addictive composition not comprising the present invention, due to making
With the feed addictive composition, the feed efficiency in individual improves and/or weightening increases and/or feed conversion rate reduces and/
Or the digestibility of the nutrients or energy in feed improves and/or nitrogen retains the negative shadow for improving and/or avoiding necrotic enteritis
Loud ability improves and/or immune response improves.
Preferably, " improved animal performance " means that feed efficiency improves and/or weightening increases and/or feed conversion rate drop
It is low.
The term as used herein " feed efficiency " refers to that quantity-unlimiting feeding animals or fed to it refer to during a period of time
The amount of the weightening occurred in animal when quantitative food.
" feed efficiency of raising " means to feed with there is no the feed addictive composition of the present invention
Animal is compared, and the weightening for causing per unit to take in feed using the feed addictive composition in feed increases.
Feed conversion rate (FCR)
The term as used herein " feed conversion rate " refers to feeding to make to measure as defined in the weight gain of animal to animal
Forage volume.
Improved feed conversion rate means lower feed conversion rate.
" lower feed conversion rate " or " improved feed conversion rate " means to combine using feed addictive in feed
Object causes required feeding when the weight of animals increase specified amount to be less than in the feed not comprising feed addition to the forage volume of animal
Required forage volume when the weight of animals being made to increase equal amount when agent composition.
Nutrient digestibility
What Nutrient digestibility used herein meant to disappear from the specified section (such as small intestine) of gastrointestinal tract or gastrointestinal tract
The score of nutrients.Nutrient digestibility can measure for be applied to individual with from individual excrement come out between difference,
Or be applied to individual be retained in gastrointestinal tract specify section (such as ileum) on digest between difference.
Nutrient digestibility used herein can measure taken in nutrition by collecting total excreta during a period of time
Difference between object and the nutrients drained;Or utilize and will not be absorbed by animal, and researcher is allowed to calculate entire gastrointestinal tract
Or the inert labels of the amount of the nutrients to be disappeared in gastrointestinal tract section measure.This inert labels can be titanium dioxide,
Chromium oxide or acid-insoluble ash.Digestibility is represented by percentage of the nutrients in feed, or is expressed as digestible battalion
Support the mass unit of the nutrients in mass unit/feed of object.
Nutrient digestibility used herein covers starch digestibility, fat digestibility, protein digestibility and amino acid
Digestibility.
Energy digestibility used herein means that consumed feed gross energy subtracts the gross energy of excrement, or consumed
Feed gross energy subtracts the gross energy for the remaining digest that animal gastrointestinal tract is specified on section (such as ileum).Generation used herein
It can refers to Apparent metabolizable energy to thank, and means that consumed feed gross energy subtracts and contain in excrement, urine and the gaseous product of digestion
Gross energy.Energy digestibility and metabolic energy can measure specifies section for drained in the intake of gross energy and excrement or gastrointestinal tract
Present in difference between gross energy in digest, using method identical with the digestibility of nutrients is measured, for
Elimination of nitrogen carries out appropriate correction to calculate the metabolic energy of feed.
Nitrogen retains
Nitrogen used herein retains the ability for meaning individual from diet retained nitrogen as weight.It is more than daily in the excretion of nitrogen
Intake when occur negative nitrogen balance and to be frequently observed the negative nitrogen balance when losing muscle.Positive nitrogen equilibrium is often given birth to muscle
It is long related, it is especially related to the muscle growth in the animal just grown.
Nitrogen, which retains, to be measured as absorbed nitrogen by means of total collection of the excreta during a period of time and urine and be drained
Nitrogen between difference.It is drained it should be understood that the nitrogen drained includes non-digesting protein, endogenous protein from feed
Object, microprotein and urinary nitrogen.
Survival rate
The term as used herein survival rate means the number of the individual still to live.Term " improved survival rate " can be
Another saying of " death rate of reduction ".
Dressing percentage and meat productivity
The term as used herein dressing percentage means after business or the slaughtering process of experiment, ratio as live weight
Trunk amount.Term trunk means the animal bodies butchered by food, wherein head, internal organ, the part of four limbs and feather or skin
Skin has removed.The term as used herein meat productivity means the amount of the edible meat of the ratio as live weight, or as live body
The amount of the specified meat of the cutting of the ratio of weight.
Weightening
The present invention also provides the methods for increasing the weightening in individual (such as poultry or pig) comprising gives individual feeding packet
The feed of feed addictive composition containing the present invention.
" increased weightening " refers to compared with the animal for the feed that feed addictive composition is not present with feeding, is wrapped in feeding
Animal has increased weight when feed containing the feed addictive composition.
Increased weightening can be at least 0.5%, at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, extremely
Few 12%, at least 15%, at least 20% or at least 30%.In some embodiments, which can be at least 50% or extremely
Few 100%.
The increase of weightening can be that just in contrast, in the control, used feed does not include DMF and high dose
(i.e.>1500FTU/kg feeds) phytase.On the other hand, the increase of weightening can be just comprising another inositol six
For the use of the feed of phosphatase, wherein the phytase with low dosage (such as<1000FTU/kg feeds) it uses.
Clinical or subclinical enteropathy attack
In one embodiment, there is clinical or subclinical enteropathy attack in individual.
In one embodiment, the attack of clinical or subclinical enteropathy can be by arbitrary pathogen or arbitrary pathogenic bacteria (such as
C.perfringens or Escherichia coli) cause.
Term " clinical disease " means that anatomy to be enough to generate identifiable disease indication and symptom or physiology change
Become the stage of the course of the pathological conditions started.
Term " subclinical disease " means or is related to noticing the course of disease stage before symptom for the first time.
Enteropathy can be the arbitrary intestines infection that individual can be suffered from.
In an example, enteropathy can be caused by genic organisms (such as pathogenic bacteria).
In one embodiment, enteropathy can be caused by one or more in following organism:Pathogenic fusobacterium
Species, such as C.perfringens and/or clostridium difficile and/or Escherichia coli and/or Salmonella ssp and/or bent stick
Ella species.
In one embodiment, enteropathy can be caused by one or more in following pathogen:C.perfringens
And/or clostridium difficile and/or Escherichia coli, preferably C.perfringens and/or clostridium difficile, more preferable C.perfringens.
Necrotic enteritis
Necrotic enteritis is the acute or chronic enterotoxemia observed in chicken, turkey and duck in world wide, by
C.perfringens causes.Necrotic enteritis is often characterized as the cellulosic necrotic enteritis of typically mid-small bowel.The death rate
Can be 5% to 50%, normally about 10%.Infection broadcasts life by excrement-oral instructions.The spore resistance of genic organisms is high.It lures
Cause of disease element includes globidiosis, diet (high protein), may attach most importance in duck stress, high viscosity diet (include often with diet
A large amount of rye is related to wheat), the feed that pollutes and/or water, other wasting diseases.
The present invention relates to increase method of the individual to the resistance of necrotic enteritis.In other words, the present invention relates to avoid or subtract
The negative effect of light necrotic enteritis.
The term as used herein " resistance " can cover term " tolerance ".Therefore, in one embodiment, individual can be with
Necrotic enteritis can be resistant to necrotic enteritis non-resistant but individual, i.e., to the performance of individual without negative effect.
In one embodiment, it the present invention relates to the feed addictive composition of the present invention, is used to control in individual
Treat or prevent necrotic enteritis.In general, individual can be by or will be by C.perfringens and/or eimeria
(Eimeria) individual of species attack.This attack may be from environment, or apply viable microbial, example in feed or drinking water
Such as when using coccidial vaccine living.
In another embodiment, the present invention relates to feed addictive composition, be used in individual prevent and/or
Treat globidiosis.
The method that the present invention furthermore provides prevention and/or treats necrotic enteritis and/or globidiosis, wherein to individual
Using the feed addictive composition of a effective amount of present invention.
Immune response
Immune response used herein means that DFM adjusts one of multiple modes of immune system of animal, including increases
Antibody generates, raises cell-mediated immune, up-regulation proinflammatory cytokine and increase toll sample receptor signal grantings.It should be understood that
DFM can be conducive to the immunostimulation of gastrointestinal tract host is protected to resist the disease, and can be right to the immunosupress of gastrointestinal tract
Host is advantageous, this is because less nutrients and energy be used to support immune function.
Preferably, immune response is cell immune response.
Preferably, immune labeled immune response is measured by observing.
Pathogenic bacteria
The term as used herein pathogenic bacteria mean such as toxigenicity clostridium species, such as C.perfringens and/or large intestine
Bacillus and/or Salmonella ssp and/or campylobacter species.In one embodiment, pathogenic bacteria can be fowl cause
Characteristic of disease species Escherichia coli.
The present invention can reduce the pathogenic bacteria population in individual gastrointestinal tract.
Nutrients is drained
In one embodiment, the present invention relates to the nutrients reduced in muck excretions.This is to reducing environmental hazard tool
There is positive effect.For example, in preferred embodiments, the present invention relates to the nitrogen and/or phosphorus content that reduce in individual muck.Cause
This, this can reduce the amount of nitrogen and/or phosphorus in environment, this can be advantageous.
Probiotics (probiotic)
For some applications, it is believed that the DFM in the present composition can play probiotic bacterial cultures effect.To the present invention's
Composition adds other probiotics and/or probiotics are also within the scope of the invention.
Here, probiotics is:
" non-digestible food ingredients, by selective stimulating is a kind of or the growth of the beneficial bacteria of limited quantity and/or
Activity and advantageously influence host ".
The term as used herein " probiotic bacterial cultures " definition viable microbial (e.g., including bacterium or yeast), in example
Can advantageously influence host organisms when such as applying with sufficient amount intake or part, i.e., by assign host organisms it is a kind of or
A variety of verifiable health benefits.Probiotics can improve the microbial balance of one or more mucomembranous surfaces.For example, mucous membrane table
Face can be intestines, urethra, respiratory tract or skin.The term as used herein " probiotics ", which is also covered by, can stimulate the beneficial of immune system to divide
Branch and the viable microbial for reducing the inflammatory reaction in mucomembranous surface (such as intestines) simultaneously.
Although for probiotics absorbs, lower limit or the upper limit is not present, it has been proposed that at least 106-1012, preferably at least
106-1010, preferably 108-109Cfu will be effective to reaching beneficial health effect in individual as daily dose.
Separation
On the one hand, expediently, enzyme used in the present invention or DFM can be the forms of separation.Term " separation " is anticipated
Refer to enzyme or DFM least substantially at without the enzyme or DFM in nature it is natural associated or see in nature at least one
Kind other compositions.The enzyme or DFM of the present invention can be substantially free of the originally associated one or more pollutants of the substance
Form provide.Thus, for example, it can be substantially free of the polypeptide of one or more potential pollutions and/or nucleic acid molecules.
Purifying
On the one hand, it is preferable that enzyme and/or DFM of the invention is the form of purifying.Term " purifying " mean enzyme and/
Or DFM exists with high level.Enzyme and/or DFM advantageously main component present in composition.Preferably, it is at least about
90%, or at least about 95% or at least about 98% horizontal exists, the level be relative to the total composition considered with dry weight/
It is measured based on dry weight.
Imagine within the scope of the invention, embodiment of the present invention can be combined so that arbitrary characteristics as described herein
Combination be included within the scope of the present invention.Specifically, imagining within the scope of the invention, bacterium can be showed simultaneously
Any one of therapeutic effect.
With reference to the following drawings and embodiment, only description description is of the invention by way of example.
Embodiment
Embodiment 1
Method
It is bought from commercial hatchery and amounts to 1600 1 age in days Cobb male chick.When studying beginning, subregion (block)
50 male chick are distributed to each processing henhouse (pen).Research is made of (table 1) following processing:
The experimental design of 1. embodiment 1 of table
Different diet | C.perfringens is attacked | Phyzyme XP1 | DFM (CFU/g feeds)2 |
1 | It is no | 500FTU/kg | Nothing |
2 | It is | 500FTU/kg | Nothing |
3 | It is | 500FTU/kg | Enviva Pro(7.5x 104CFU/g) |
4 | It is | 3000FTU/kg | Enviva Pro(7.5x 104CFU/g) |
1Phyzyme XP are the 6-phytases from Escherichia coli provided by Danisco A/S BJ Rep Office.
2EnvivaBe bacillus subtilis strain Bs2084, the LSSAO1 provided by Danisco A/S BJ Rep Office and
The combination of 15AP4.
Start in research, the 23rd day, the 35th day and terminate to record the chicken weight of each henhouse when (the 42nd day).Henhouse is to survey
Measure unit.The feeding dorking diet in the form of clast (opened guideway) or pellet (growth material and fattening are expected).Diet meets or more than NRC
Standard (table 2).Mixer is rinsed to prevent diet cross contamination.All processing feeds are mixed with Davis S-20 mixers to be used in combination
California pellet mills pill (cold pellet temperature is 65 DEG C to 70 DEG C).Since each batch, it is intermediate and terminate from every
One processing diet is collected sample and is blended together to confirm enzymatic activity and the Enviva Pro presence in feed.
The experiment diet of 2. embodiment 1 of table forms
Chicken quantity-unlimiting feed received suitable for the processing from the 0th to 42 day.Enzyme and Enviva Pro are by Danisco to be suitble to
Mixture for all experiment process and horizontal offer.Henhouse, which is arranged in facility, to be prevented from being in direct contact, to avoid pollution.
Growth material is changed to by opened guideway at the 23rd day.At the 35th day growth material was substituted with fattening material.When changing feed every time, subregion
Feeder is pipetted from henhouse, is weighed again, empty and reloads processing diet appropriate.Research last day to feed
It weighs.Daily henhouse is checked for the death rate.When chicken is eliminated or finds death, record date and removal weight
(Kg).Gross necropsy is implemented to determine gender and the possible cause of death to all dead or superseded chicken.Pay attention to gangrenosum acne intestines
Scorching sign.
All henhouses all have about 4 inch straw in a mattress, have one layer of fresh pine bits.
Spraying vaccine is carried out to it with business coccidiosis vaccine (Coccivac-B) before all chickens are positioned over henhouse
Inoculation.At the 20th, 21 and 22 day, in addition to processing 1, all chickens are given with the broth culture of C.perfringens.Using known
The field separation strains of NE and the C.perfringens from commercial meat chickens operation can be caused as challenge organism.Daily using new
Fresh inoculum.Titer level is about 1.0 × 108-9.Each henhouse receives same amount of inoculum.It is raised by being mixed into tubular type
It feeds and applies inoculum in feed present in device base portion.At the 23rd day, 5 chickens are selected from each henhouse, implement euthanasia, point
Group is weighed, and check necrotic enteritis damage there are degree.Scoring is based on 0 to 3 point, wherein 0 is normal, and 3 be most serious
(0=is without 1=is slight, 2=moderates, and 3=is notable/serious;Hofacre etc., 2003J.Appl.Poult.Res.12:60–64).
Adjoint medicinal treatment is not used during research.
Average value is detached with paired t-test.Think in P<0.05 time with significant difference.It is single using henhouse as experiment
Member.
As a result
From the 23rd day up to off-test as shown in (Fig. 1), C.perfringens attack substantially reduce weight gain.It mends
It fills Enviva Pro and significantly improves the weight gain of each sample day to the level of positive control.But further supplement high flesh
Alcohol six-phosphatase dosage (processing 10) improve weight to the 12nd, 23 and 35 day the level for being significantly higher than positive control and the 42nd day
Numerically bigger level.
As from the 23rd day shown in the off-test (Fig. 2), C.perfringens attack significantly improves feed conversion rate
(FCR).Enviva Pro are added into diet causes FCR to be significantly reduced from negative control.But supplement high phytase
Dosage reduces FCR to the identical level with seen in positive control.
Supplement Enviva Pro make the death rate observed reduce (Fig. 3), supplement high phytic acid enzyme dosage make its into
One step numerically reduces.This severity that can be construed to C.perfringens attack reduces, this is high six phosphorus of inositol of supplement
The seen Injury score numerically reduced supports (Fig. 4) when sour enzyme dosage, which is markedly different from the damage of positive control
Wound scoring.
With using Enviva Pro high phytic acid is utilized compared with the phytase of standard (500FTU) dosage
Enzyme dosage (3000FTU/kg) and the combination of Enviva Pro have apparent benefit, this is the FCR reduced and increased weightening
It is proved.These benefits are construed to reduced damage of intestines.
Embodiment 2
Material and method
The male chick of 1040 1 age in days Cobb x Cobb 500 is amounted to from commercial hatchery purchase.When studying beginning,
Subregion is randomly assigned 10 chick to Petersime chicken coops by each processing.Only selection healthy chicken is for testing, and is entirely studying
Do not replace chicken in the process.Research is made of (table 1) following processing:
The experimental design of 1. embodiment 2 of table
1Enviva Pro are the combination of bacillus subtilis strain Bs2084, LSSAO1 and 15AP4, by Danisco public affairs
Department provides, and is added by 75,000CFU/g feeds.
2AxtraPhyTMIt is the 6-phytase from Buttiauxella, is provided by Danisco A/S BJ Rep Office.
Chicken weight is recorded when research starts (the 0th day) and the 13rd day, the 21st day and research terminates (the 28th day).Chicken coop is
Measuring unit.Diet is fed in the form of thickener, and is formulated as meeting or more than NRC standards (table 2).Mixer is rinsed to prevent day
Cross contamination between grain.Since each batch, it is intermediate and terminate from each processing diet collection sample and mix use
In analyzing enzymatic activity in feed and DFM exists.
The experimental diets of 2. embodiment 2 of table form
All chicken feeding " business style " daily rations are until the 9th day;From the 10th day, feeding processing daily ration.Changing feed
When, feeder is pipetted from henhouse, is weighed again, empties and reloads processing diet appropriate.In the last day pair of research
Feed is weighed.Daily henhouse is checked for the death rate.When chicken is eliminated or finds death, record date and removal weight
(Kg).Gross necropsy is implemented with the possible cause of death of determination to all dead or superseded chicken.Record the mark of necrotic enteritis
As.Chicken can get the quantity-unlimiting feed of proper treatment during entire research.
Disease induction is carried out according to study site Standard Operating Procedure (SOP).In short, at the 13rd day, all chickens are all used
Eimeria maxima (Eimeria maxima) oral vaccination, inoculum contain every chicken about 5,000 egg capsule.At the 18th day,
In addition to processing 1 and 3, all chickens all receive the broth culture of C.perfringens, which contains about 108cfu/ml.Institute
There is processing henhouse to receive same amount of inoculum.By fresh to be administered once a day in the feed that is mixed into feeder base portion
C.perfringens inoculum, using three days (the 18th, 19 and 20 day).At the 21st day, 3 chickens are selected from each henhouse, are implemented
Euthanasia, grouping weighs, and check necrotic enteritis damage there are degree.Scoring is based on 0 to 3 point, wherein 0 be it is normal, and 3
It is that (0=is without 1=is slight, 2=moderates, and 3=is notable/serious for most serious;Hofacre etc.,
2003J.Appl.Poult.Res.12:60–64).Adjoint medicinal treatment is not used during research.
For showing data, using JMP softwares, the effect of processing is examined with ANOVA, is used in combination paired t-test separation average
Value.Think in P<0.05 time with significant difference.Using chicken coop as experimental considerations unit.For pH and organ weight data, every
Chicken is experimental considerations unit.
In order to examine interaction, main effect and their phase including phytase and Enviva Pro are used
The factorial arrangement of interaction, with the subgroup of ANOVA analyzing processings (processing 4 to 13).
As a result
Compared with control not under fire, weightening (BWG) and feed conversion rate (FCR) with regard to the 21st day and the 28th day and
Speech, C.perfringens significantly reduce the performance (for T1 to T2, T3 is to T4) (table 3) of chicken.Lacking C.perfringens attack
In the case of, the reduction of diet P does not influence the BWG of the 21st day or the 28th day.But it is attacking there are C.perfringens
In the case of, there are the reductions of significant numerical value between high P diets and low P diets by BWG.These observation results are consistent with the data of FCR.
In individually supplement phytase, there is variable effect to the performance of chicken;But in all cases,
There are numerical value to improve to the horizontal level higher than low P diets (T4) under fire by 21 days BWG.It is being obtained the results show that
Under conditions of necrotic enteritis attack, the performance of chicken is not further improved in high phytic acid enzyme dosage;Because in 10,000FTU
The minimum BWG only with phytase treatment is found under the phytase (T8) of dosage, this is markedly different under fire
Low P diets (T4).Equally, at the 28th day, in individually supplement phytase, BWG is in the inositol six higher than 1500FTU
There are numerical value reductions under phosphatase level.
In individually supplement Enviva Pro (T9), the 21st day BWG is significantly improved from low P diets (T4) under fire, and
The 28th day further improve to low level of the P diets without significant difference not under fire.For FCR, Enviva Pro
There is the significant decrease from control under fire in supplement, but be not enough to the negative effect completely to attack resistance.
When combination, compared with when individually supplementing phytase, the 21st day and the 28th day, six phosphorus of inositol of high dose
Sour enzyme and Enviva Pro lead to more uniform reaction for BWG.For FCR, which existed at the 21st day (Fig. 5)
Synergistic effect.In individually supplement phytase, there is performance at 500,1500 (T7) and 3000FTU/kg levels
Improve (reduction of FCR), and under conditions of necrotic enteritis attack more than phytic acid enzyme dosage when there are the drops of performance
It is low.But in combination be added probiotics when, with only at most and include 3000FTU horizontal processing (T12) compared with, FCR mono-
Causing ground, there are numerical value reductions.But at 10,000FTU (T13), there are big to be substantially reduced, and causes in all processing groups
Minimum FCR.In specific effect (the excluding positive control T1, T2 and T3) for investigating combination, there is combination to the 21st day FCR
Significantly affect (P=0.0319) (table 4).
The reduction of diet AvP causes substantially reducing (table 3) for shin bone bone ash, shin bone bone ash to be the instructions of phosphorus bioavailability
Object.C.perfringens attack causes the small numerical value of tibial bone ash content to reduce, this may be that the intestines caused by infection damage
Wound reduces the ability that intestines effectively absorb nutrients.Individually supplement phytase cause shin bone bone ash % restore to not by
High level of the P diets (T1) without significant difference of attack.In individually supplement Enviva Pro (T9), shin bone bone ash % numerical value increases
The level higher than low P diets (T3) not under fire is added to, this demonstrate that the product fights production for the reduction of shin bone bone ash
The ability of the influence of gas capsular clostridium attack, this may indicate that the recovery of gut function.When supplementing the combination, exist to inositol six
The dose response of phosphatase reaches the level higher than high P diets (T1) not under fire at 3000FTU, in individually supplement flesh
This improvement is not observed when alcohol six-phosphatase.
The processing of table 3. is to performance parameter, feed intake, weightening, the influence of feed conversion rate and the 21st day bone ash data
The combination of 4. phytase+Enviva Pro of table is significantly affected on the 21st day FCR's
C.perfringens attack, which has the death rate and Injury score, to be significantly affected (table 4).It is under fire not dead in group
The shortage of rate and the shortage of Injury score show under fire group and under fire there is no pollutions between group.With regard to Injury score
Speech is all not present under arbitrary phytase level between phytase and EnvivaPro+ phytases and shows
Write difference (T4-8 is to T9-13).But 1500 (T6) and 3000FTU (T7) are handled, only using phytase treatment
Low P diets under fire level on there are the increases of the numerical value of the death rate.The addition of EnvivaPro cause the death rate from by
Attack low P diets significantly reduce, with only with phytase treatment compared with, also reduce the phytase agent of combination
The variation of the death rate between amount.
Influence of the processing of table 5. to the death rate (%) and necrotic enteritis (NE) Injury score
Embodiment 3
Method
It is bought from commercial hatchery and amounts to 1080 1 Japanese instar chicklings.When studying beginning, subregion divides at random to each henhouse
With 15 chick.Research forms (table 1) by following processing, each processing has 8 repetition henhouses.
Table 1:Experimental design
1EnvivaIt is the combination of bacillus subtilis strain Bs2084, LSSAO1 and 15AP4, by Danisco
Company provides.
2Axtra Phy are six phosphorus of 6- inositols from Buttiauxella that can be obtained from Danisco Animal nutrition company
Sour enzyme.
Research start (the 0th day), the 6th day, the 21st day and research terminate (the 35th day) when record chicken weight.Henhouse is to survey
Measure unit.It prepares diet and instructs (table 2) to meet NRC.All processing feeds use Davis S-20 mixers to mix.In diet
Between rinse mixer to prevent the cross contamination of diet.Since each batch, it is intermediate and terminate from each processing diet
Sample, mixing are collected, and is analyzed, to confirm enzymatic activity and the DFM presence in feed.Diet is fed in the form of thickener.
All henhouses all have about 4 inch straw in a mattress, have one layer of fresh pine bits.All chickens are being put into henhouse prosopyle
Clothes receive business coccidiosis vaccine.
Table 2:Experimental diets form
All chickens fed business style opened guideway daily ration from the 0-6 days.From the 7th day, growth material of the feeding suitable for processing
Diet is until the 21st day.Terminated fattening material diet of the feeding in (the 35th day) suitable for processing from the 21st day to research.Changing feed
When, feeder is pipetted from henhouse, is weighed again, empties and reloads processing diet appropriate.In the last day pair of research
Feed is weighed.Daily henhouse is checked for the death rate.When chicken is eliminated or finds death, record date and removal weight
(Kg)。
For showing data, average value is detached with paired t-test.Think in P<0.05 time with significant difference.Use chicken
House is used as experimental considerations unit.
As a result
Feed conversion rate (FCR) significantly improves when individually the dosage of increase phytase does not result in 35 age in days.Institute
There are addition Enviva Pro under phytic acid enzyme level to reduce FCR.As phytic acid enzyme dosage increases, from addition
The benefit of Enviva Pro also increases.Horizontal phytase generation is contained up to contain and the diet without Enviva Pro
Between FCR maximum difference.
Table 3:Performance results
Under higher phytic acid enzyme dosage, compared with when individually supplementing phytase, Enviva is supplemented
The numerical value that there is weightening (BWG) when Pro increases (table 3).It is not observed under minimum phytic acid enzyme dosage (500FTU)
This effect.
Embodiment 4
Material and method
1 age in days Cobb male chick is bought from commercial hatchery.When studying beginning, subregion is randomly assigned to each chicken coop
10 males.Each processing has 8 repetition chicken coops.Research is made of (table 1) following processing.
Table 1:The experimental design of embodiment 4
1HiPhos is Ronozyme HiPhos, including the phytase from Bu Shi citric acid bacteriums, it can be from Supreme Being
Si Man/Novozymes Company obtains.
2EnvivaIt is the combination of bacillus subtilis strain Bs2084, LSSAO1 and 15AP4, by Danisco
Company provides.
Chicken weight is recorded when research starts (the 0th day), the 21st day and research terminate (the 28th day).Chicken coop is to measure list
Position.Diet meets or more than NRC standards (table 2).All processing feeds use Davis S-20 mixers to mix.Between diet
Mixer is rinsed to prevent the cross contamination of diet.Since each batch, it is intermediate and terminate from the collection of each processing diet
Sample is simultaneously blended together, to confirm enzymatic activity and the Enviva Pro presence in feed.
Table 2:The experimental diets of embodiment 4 form
Daily ration is until the 9th day before all chicken feeding business opened guideways;From the 10th day, feeding processing daily ration.It is raised changing
When material, feeder is pipetted from chicken coop, is weighed again, empty and reloads processing diet appropriate.In the last day of research
It weighs to feed.Daily chicken coop is checked for the death rate.When chicken is eliminated or finds death, record date and removal weight
It measures (Kg).Gross necropsy is carried out with the possible cause of death of determination to all dead or superseded chicken.Record necrotic enteritis
Sign.Chicken can get the quantity-unlimiting feed of proper treatment during entire research.
Disease induction is carried out according to study site Standard Operating Procedure (SOP).In short, at the 13rd day, all chickens are all used
Eimeria maxima oral vaccination, inoculum contain every chicken about 5,000 egg capsule.At the 18th day, in addition to processing 1 and 3, own
Chicken all receives the broth culture of C.perfringens, which contains about 108cfu/ml.All processing henhouses receive identical
The inoculum of amount.By being administered once a day fresh C.perfringens inoculation in the feed that is mixed into feeder base portion
Object, using three days (the 18th, 19 and 20 day).At the 21st day, 3 chickens being selected from each henhouse, implement euthanasia, grouping is weighed,
And check necrotic enteritis damage there are degree.Scoring is based on 0 to 3 point, wherein 0 is normal, and 3 be that (0=is without 1 for most serious
=slight, 2=moderates, 3=are notable/serious;Hofacre etc., 2003J.Appl.Poult.Res.12:60–64).In the research phase
Between do not use adjoint medicinal treatment.
At the 21st day, each chicken coop measured the pH of the ileum digest of 2 chickens.It is visited by the way that Sensorex lances are punctured pH
Needle is inserted into each segment to measure the pH of digest.In two chickens, gizzard is also taken out, and weigh.At the 21st day, two chickens are taken out
Right shin bone, be dried overnight and weigh at 100 DEG C;Then fat-extraction, and 600 DEG C of burnings in Muffle furnace are carried out to sample
16 hours, to measure not fatty bone ash.Then by percentage bone ash be calculated as remaining bone ash tumour with it is dry fat-free
The ratio of bone weight is multiplied by 100.
Statistical analysis
For showing data, average value is detached with paired t-test.Think in P<0.05 time with significant difference.Use chicken
Cage is as experimental considerations unit.
As a result
In the case where necrotic enteritis is attacked, increasing the dosage of HiPhos causes 21 age in days feed conversion rates to improve (figure
7;The more feeds of per unit weightening).Enviva Pro, which are added, under all levels comprising phytase causes to reduce
(improved FCR).In the case where containing up to horizontal phytase (3000FTU/kg), the addition of Enviva Pro gradually subtracts
The weak FCR arrived in 1500FTU/kg observed at doses is improved.
Table 3:Performance results from embodiment 4
Effect of gain of the Enviva Pro on phytase is in high phytic acid enzyme dosage (3000FTU/kg)
Under significantly, wherein compared with control treatment not under fire, increase weight without significant difference.
Influence of the phytase to shin bone bone ash percentage under fire compares no significant difference with feminine gender, shows even
At high doses, phytase does not make significant difference (Fig. 8) to the shin bone bone ash in the case of attack yet.But such as institute in table 4
See, the addition of Enviva Pro significantly improves shin bone bone ash percentage, makes it close in highest phytic acid enzyme dosage
The percentage observed in positive not under fire control under (3000FTU/kg).
Table 4:Other electrophysiology measurements from embodiment 5
The ileum pH that high-level phytase (3000FTU/kg) is improved the 21st day is more than related control, and Enviva
The addition of Pro makes it reduce, and with Enviva Pro, individually minimum pH is observed in processing.In under fire negative control and maximum dose level
Hi Phos (3000FTU/kg) in observe minimum gizzard weight.The addition of Enviva Pro is under 3000FTU/kg dosage
Gizzard weight is numerically increased, but not significantly.
Attack significantly improves the death rate, and the addition of phytase reduces the death rate.Combination with Enviva Pro into
One step reduces the death rate.
All publications mentioned in description above are hereby incorporated by reference.To those skilled in the art, it shows
And be clear to, described the method for the present invention and system can be made without departing substantially from scope and spirit of the present invention
Numerous modifications and variations.Although specific preferred embodiment has been combined to describe the present invention, it should be appreciated that claimed
Invention should not undeservedly be limited to this kind of specific embodiment.In fact, the mode for carrying out the present invention to biology
Obvious a variety of modifications are intended in following following claims for chemistry and biotechnology or various equivalent modifications
Within the scope of.
Claims (45)
1. the performance for improving individual, or the digestibility for improving the raw material in feed, or retain for improving nitrogen, or use
It absorbs and retains in improving diet phosphorus, or the effect of for improving phytase, or for improving feed conversion rate
(FCR), or for improving the weightening in individual, or for improving the feed efficiency in individual, or for adjusting the immune of individual
Reaction, or the population for reducing the pathogenic bacteria in individual gastrointestinal tract, or the side for reducing the excretion of the nutrients in muck
Method, the method includes the combinations at least one Direct-Fed Microbials (DFM) and phytase of individual application, wherein
The phytase is applied to the individual by the dosage more than 1500FTU/kg feeds.
2. the purposes of the combination of at least one Direct-Fed Microbials and phytase, wherein phytase are by being more than
The dosage of 1500FTU/kg feeds uses, the performance for improving individual, or the digestibility for improving the raw material in feed, or
Retain for improving nitrogen, or absorb and retain for improving diet phosphorus, or the effect of for improving phytase, or is used for
Improve feed conversion rate (FCR), or for improving the weightening in individual, or for improving the feed efficiency in individual, or is used for
The immune response of individual, or the population for reducing the pathogenic bacteria in individual gastrointestinal tract are adjusted, or for reducing in muck
Nutrients is drained.
3. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials are that antipathogen Direct-fed is micro-
Biology.
4. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials are bacteriums living.
5. the method or purposes of claim 1 or claim 2, wherein pressing more than the dosage of 2000FTU/kg feeds to described
Body applies the phytase.
6. the method or purposes of claim 1 or claim 2, wherein pressing more than the dosage of 3000FTU/kg feeds to described
Body applies the phytase.
7. the method or purposes of claim 1 or claim 2, wherein composition include at least three kinds of Direct-Fed Microbials.
8. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials are to inhibit the intestines of pathogenic microorganisms
The bacterial strain inside colonized.
9. the method or purposes of claim 8, wherein the pathogenic microorganisms is C.perfringens or Escherichia coli, or both
Combination.
10. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials include in subordinate
One or more bacteriums:Bacillus, enterococcus spp, Pediococcus, saccharomyces, Bifidobacterium, Propionibacterium, breast
Bacillus, lactococcus, aspergillus and combinations thereof.
11. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials include in following species
One or more bacteriums:Bacillus subtilis, bacillus licheniformis, bacillus amyloliquefaciens, Bacillus cercus, dung intestines
Coccus, Pediococcus acidilactici, saccharomyces cerevisiae, animal bifidobacteria animal subspecies, lactobacillus reuteri, Lactobacillus rhamnosus, acidophilus breast
Bacillus, Lactobacillus brevis, Lactobacillus salivarius subspecies, Lactobacillus farciminis, Lactococcus lactis, Lactobacillus casei, Lactobacillus salivarius,
Lactobacillus rhamnosus, clostridium butyricum, aspergillus oryzae, production propionibacterium acide-propionici, propionibacterium jensenii, enterococcus faecium, Pediococcus acidilactici
And combinations thereof.
12. the method or purposes of claim 1 or claim 2, wherein Direct-Fed Microbials are one in following bacterial strain
Or it is multiple:Bacillus subtilis BS18 (NRRL B-50633), bacillus subtilis BS278 (NRRL 50634), withered grass gemma
Bacillus 4-7d (NRRL B-50505), bacillus subtilis 3-5h (NRRL B-50507), bacillus subtilis AGTP BS3BP5
(NRRL B-50510), bacillus subtilis BS918 (NRRL B-50508), bacillus subtilis AGTP BS1013 (NRRL-
50509), bacillus subtilis AGTP 944 (NRRL B-50548), bacillus subtilis AGTP BS442 (NRRL B-
50542), bacillus subtilis AGTP BS1069 (NRRL B-50544), bacillus subtilis AGTP BS521 (NRRL B-
50545), bacillus subtilis BS2084 (NRRL B-50013), bacillus subtilis LSSA01 (NRRL B-50104), withered grass
Bacillus B27 (NRRL B-50105), bacillus subtilis 3A-P4 (PTA-6506), bacillus subtilis 15A-P4 (PTA-
6507), bacillus subtilis 22C-P1 (PTA-6508), bacillus subtilis BL21 (NRRL B-50134), lichens gemma bar
Bacterium BL21 (NRRL B-50134), bacillus licheniformis 3-12a (NRRL B-50504), bacillus licheniformis 4-2a (NRRL B-
50506), bacillus licheniformis 842 (NRRL B-50516), production propionibacterium acide-propionici P261 (NRRL B-50131), production propionic acid
Propionibacterium P179 (NRRL B-50133), production propionibacterium acide-propionici P169 (PTA 5271), production propionibacterium acide-propionici P170
(PTA 5272), propionibacterium jensenii P63 (NRRL B-30979), propionibacterium jensenii P195 (NRRL B-50132), lactic acid
It is galactococcus ID7 (PTA 6103), Lactococcus lactis JD19 (PTA 6104), lactobacillus acidophilus A2020 (NRRL B-30977), thermophilic
Lactobacillus lactis A4000h (NRRL B-30978), lactobacillus acidophilus PIBc6 (NRRL B-50103), Lactobacillus brevis LBR 1000
(NRRL B-30982), Lactobacillus casei LC222 (NRRL B-30983), family name's lactobacillus PLCB6 (NRRL B-50518), saliva
It is lactobacillus o246i33w (NRRL B-50102), Lactobacillus brevis AJ25 (PTA-6099), Lactobacillus brevis HE17 (PTA-6100), short
Lactobacillus 1E-1 (PTA-6509), lactobacillus lactis Cl15 (PTA-6101), lactobacillus lactis DJ6 (PTA-6102), rhamnose
Lactobacillus (CNCM I-3698), Lactobacillus farciminis (CNCM I-3699), enterococcus faecium EF141 (EN-1) (NRRL B-
30981), enterococcus faecium 2-1d (NRRL B-50519), Pediococcus acidilactici PIJe3 (NRRL B-50101), Pediococcus acidilactici
O246e42 (NRRL B-50171) and combinations thereof.
13. the method or purposes of claim 1 or claim 2, wherein phytase are 6-phytase or 3-
Phytase.
14. the method or purposes of claim 13, wherein phytase are 6-phytases.
15. the method or purposes of claim 1 or claim 2, wherein phytase are Escherichia coli phytic acids
Enzyme or Buttiauxella phytase or Citrobacter phytase or Hafnia phytic acid
Enzyme or aspergillus phytase or Penicillium phytase or trichoderma phytase or Escherichia coli
Phytase or Hansenula phytase or Peniophora category (Peniphora) phytase.
16. the method or purposes of claim 1 or claim 2, wherein DFM presses 3.75x107CFU/g feeds are to 1x1011CFU/
The dosage of g feeds exists.
17. the method or purposes of claim 1 or claim 2, wherein there is clinical or subclinical enteropathy attack in individual.
18. the method or purposes of claim 17, wherein clinical or subclinical enteropathy attack is caused by pathogenic bacteria.
19. the method or purposes of claim 18, wherein the pathogenic bacteria are C.perfringens or Escherichia coli.
20. the method or purposes of claim 1 or claim 2, wherein the digestibility is Nutrient digestibility, the adjusting
The immune response of individual is to improve the immune response of individual.
21. the method or purposes of claim 20, wherein the Nutrient digestibility is amino acid digestibility.
22. feed addictive composition, it includes the combinations of at least one Direct-Fed Microbials and phytase, wherein
Phytase is by existing below in the feed addictive composition:
A. when being added in feed by least 50g/ tonnes of (MT) feed, by 30,000FTU/g compositions or more;
B. when being added in feed by least 75g/ tonnes of (MT) feed, by 20,000FTU/g compositions or more;
C. when being added in feed by least 100g/ tonnes of (MT) feed, by 15,000FTU/g compositions or more;
D. when being added in feed by least 100g/ tonnes of (MT) feed, by 15,000FTU/g compositions or more;
E. when being added in feed by least 150g/ tonnes of (MT) feed, by 10,000FTU/g compositions or more;
F. when being added in feed by least 200g/ tonnes of (MT) feed, by 7,500FTU/g compositions or more;
G. when being added in feed by least 300g/ tonnes of (MT) feed, by 5,000FTU/g compositions or more;
And wherein Direct-Fed Microbials are pressed from 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:The range of 1FTU enzymes exists
In the feed addictive composition.
23. the feed addictive composition of claim 22, wherein Direct-Fed Microbials are pressed from 3.8x103CFU DFM:1FTU
Enzyme is to 2.0x105CFU:The range of 1FTU enzymes is present in the feed addictive composition.
24. the feed addictive composition of claim 22 or claim 23, wherein Direct-Fed Microbials are antipathogens
Direct-Fed Microbials.
25. the feed addictive composition of claim 22, wherein Direct-Fed Microbials are bacteriums living.
26. the feed addictive composition of claim 22, wherein composition include at least three kinds of Direct-Fed Microbials.
27. the feed addictive composition of claim 22, wherein Direct-Fed Microbials are the enterals for inhibiting pathogenic microorganisms
The bacterial strain colonized.
28. the feed addictive composition of claim 27, wherein pathogenic microorganisms are C.perfringens, Escherichia coli, sand
Door Salmonella species or campylobacter species, or combinations thereof.
29. the feed addictive composition of claim 22, wherein Direct-Fed Microbials include from one in subordinate
Or multiple bacterium:Bacillus, enterococcus spp, Pediococcus, saccharomyces, Bifidobacterium, Propionibacterium, lactobacillus
Category, lactococcus, aspergillus and combinations thereof.
30. the feed addictive composition of claim 22, wherein Direct-Fed Microbials include one in following species
A or multiple bacterium:Bacillus subtilis, bacillus licheniformis, bacillus amyloliquefaciens, Bacillus cercus, dung intestines ball
Bacterium, Pediococcus acidilactici, saccharomyces cerevisiae, animal bifidobacteria animal subspecies, lactobacillus reuteri, Lactobacillus rhamnosus, acidophilus breast bar
Bacterium, Lactobacillus brevis, Lactobacillus salivarius subspecies, Lactobacillus farciminis, Lactococcus lactis, Lactobacillus casei, Lactobacillus salivarius, mouse
Lee's sugar lactobacillus, clostridium butyricum, aspergillus oryzae, production propionibacterium acide-propionici, propionibacterium jensenii, enterococcus faecium, Pediococcus acidilactici and
A combination thereof.
31. the feed addictive composition of claim 22, wherein Direct-Fed Microbials are one or more in following bacterial strain
It is a:Bacillus subtilis BS18 (NRRL B-50633), bacillus subtilis BS278 (NRRL 50634), bacillus subtilis
4-7d (NRRL B-50505), bacillus subtilis 3-5h (NRRL B-50507), bacillus subtilis AGTP BS3BP5
(NRRL B-50510), bacillus subtilis BS918 (NRRL B-50508), bacillus subtilis AGTP BS1013 (NRRL-
50509), bacillus subtilis AGTP 944 (NRRL B-50548), bacillus subtilis AGTP BS442 (NRRL B-
50542), bacillus subtilis AGTP BS1069 (NRRL B-50544), bacillus subtilis AGTP BS521 (NRRL B-
50545), bacillus subtilis BS2084 (NRRL B-50013), bacillus subtilis LSSA01 (NRRL B-50104), withered grass
Bacillus B27 (NRRL B-50105), bacillus subtilis 3A-P4 (PTA-6506), bacillus subtilis 15A-P4 (PTA-
6507), bacillus subtilis 22C-P1 (PTA-6508), bacillus subtilis BL21 (NRRL B-50134), lichens gemma bar
Bacterium BL21 (NRRL B-50134), bacillus licheniformis 3-12a (NRRL B-50504), bacillus licheniformis 4-2a (NRRL B-
50506), bacillus licheniformis 842 (NRRL B-50516), production propionibacterium acide-propionici P261 (NRRL B-50131), production propionic acid
Propionibacterium P179 (NRRL B-50133), production propionibacterium acide-propionici P169 (PTA 5271), production propionibacterium acide-propionici P170
(PTA 5272), propionibacterium jensenii P63 (NRRL B-30979), propionibacterium jensenii P195 (NRRL B-50132), lactic acid
It is galactococcus ID7 (PTA 6103), Lactococcus lactis JD19 (PTA 6104), lactobacillus acidophilus A2020 (NRRL B-30977), thermophilic
Lactobacillus lactis A4000h (NRRL B-30978), lactobacillus acidophilus PIBc6 (NRRL B-50103), Lactobacillus brevis LBR 1000
(NRRL B-30982), Lactobacillus casei LC222 (NRRL B-30983), family name's lactobacillus PLCB6 (NRRL B-50518), saliva
It is lactobacillus o246i33w (NRRL B-50102), Lactobacillus brevis AJ25 (PTA-6099), Lactobacillus brevis HE17 (PTA-6100), short
Lactobacillus 1E-1 (PTA-6509), lactobacillus lactis Cl15 (PTA-6101), lactobacillus lactis DJ6 (PTA-6102), rhamnose
Lactobacillus (CNCM I-3698), Lactobacillus farciminis (CNCM I-3699), enterococcus faecium EF141 (EN-1) (NRRL B-
30981), enterococcus faecium 2-1d (NRRL B-50519), Pediococcus acidilactici PIJe3 (NRRL B-50101), Pediococcus acidilactici
O246e42 (NRRL B-50171) and combinations thereof.
32. the feed addictive composition of claim 22, wherein phytase are 6-phytase or 3- inositols
Six-phosphatase.
33. the feed addictive composition of claim 32, wherein phytase are 6-phytases.
34. the feed addictive composition of claim 22, wherein phytase are escherichia coli phytases, or
Buttiauxella phytase or Citrobacter phytase or Hafnia phytase, or
Aspergillus phytase or Penicillium phytase or trichoderma phytase or Escherichia coli inositol six
Phosphatase or Hansenula phytase or Peniophora category phytase.
35. kit, it includes the feed addictive composition of any one of claim 22 to 34 and operation instructions.
36. the method for preparing feed addictive composition comprising by least one Direct-Fed Microbials and phytic acid
Enzyme combines so that the dosage of the composition mysoinositol six-phosphatase:
A. it is 30,000FTU/g compositions or more when being added in feed by least 50g/ tonnes of (MT) feed;
B. it is 20,000FTU/g compositions or more when being added in feed by least 75g/ tonnes of (MT) feed;
C. it is 15,000FTU/g compositions or more when being added in feed by least 100g/ tonnes of (MT) feed;
D. it is 15,000FTU/g compositions or more when being added in feed by least 100g/ tonnes of (MT) feed;
E. it is 10,000FTU/g compositions or more when being added in feed by least 150g/ tonnes of (MT) feed;
F. it is 7,500FTU/g compositions or more when being added in feed by least 200g/ tonnes of (MT) feed;
G. it is 5,000FTU/g compositions or more when being added in feed by least 300g/ tonnes of (MT) feed;
And the dosage of Direct-Fed Microbials described in the feed addictive composition is from 2.5x103CFU DFM:1FTU enzymes
To 6.7x106CFU:In the range of 1FTU enzymes.
37. the method for claim 36, wherein the method further include packaging step.
38. the method for claim 36, the wherein dosage of Direct-Fed Microbials described in feed addictive composition from
3.8x103CFU DFM:1FTU enzymes are to 2.0x105CFU:In the range of 1FTU enzymes.
39. feed, it includes the feed addictive compositions of any one of claim 22-34.
40. the feed of claim 39, wherein phytase press 1500FTU/kg feeds and 20,000FTU//kg feeds it
Between dosage exist.
41. the feed of claim 39 or claim 40, wherein DFM press 7.5x104CFU/kg feeds and 1x107CFU/kg is raised
The dosage of material exists.
42. the method for preparing feed comprising combine feed ingredient with the feed addictive of any one of claim 22-34
Object mixes.
43. pre-composition, described it includes feed addictive composition and at least one minerals and/or at least one vitamin
Feed addictive composition contains the combination of at least one Direct-Fed Microbials and phytase, wherein phytic acid
Enzyme is by existing below in the pre-composition:
A. when being added in feed by least 50g/ tonnes of (MT) feed, by 30,000FTU/g compositions or more;
B. when being added in feed by least 75g/ tonnes of (MT) feed, by 20,000FTU/g compositions or more;
C. when being added in feed by least 100g/ tonnes of (MT) feed, by 15,000FTU/g compositions or more;
D. when being added in feed by least 100g/ tonnes of (MT) feed, by 15,000FTU/g compositions or more;
E. when being added in feed by least 150g/ tonnes of (MT) feed, by 10,000FTU/g compositions or more;
F. when being added in feed by least 200g/ tonnes of (MT) feed, by 7,500FTU/g compositions or more;
G. when being added in feed by least 300g/ tonnes of (MT) feed, by 5,000FTU/g compositions or more;
And the Direct-Fed Microbials are pressed from 2.5x103CFU DFM:1FTU enzymes are to 6.7x106CFU:The range of 1FTU enzymes exists
In the pre-composition.
44. pre-composition, it includes the feed addictive compositions of any one of claim 22-34 and at least one minerals
And/or the combination of at least one vitamin.
45. the feed addictive composition of any one of claim 22-34, the pre-composition of claim 43 or 44 or right are wanted
Seek use of the feed of any one of 39-41 in preparing the drug for preventing and/or treating necrotic enteritis and/or globidiosis
On the way.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1213801.2 | 2012-08-03 | ||
GBGB1213801.2A GB201213801D0 (en) | 2012-08-03 | 2012-08-03 | Feed additive composition |
US13/827,730 US9179693B2 (en) | 2012-08-03 | 2013-03-14 | Feed additive composition |
US13/827,730 | 2013-03-14 | ||
PCT/EP2013/066247 WO2014020138A2 (en) | 2012-08-03 | 2013-08-02 | Feed additive composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104684408A CN104684408A (en) | 2015-06-03 |
CN104684408B true CN104684408B (en) | 2018-08-31 |
Family
ID=
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058638A1 (en) * | 2002-12-23 | 2004-07-15 | Universität Tübingen | Method for the production of nitrate-containing precursors for metal oxides and oxocuptrate superconductors |
CN101035892A (en) * | 2004-10-04 | 2007-09-12 | 诺维信公司 | Polypeptides having phytase activity and polynucleotides encoding same |
WO2007112739A1 (en) * | 2006-04-04 | 2007-10-11 | Novozymes A/S | Phytase variants |
CN101756069A (en) * | 2009-12-16 | 2010-06-30 | 湖南农业大学 | High-efficiency and environment-friendly feed additive for pigs and preparation method thereof |
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058638A1 (en) * | 2002-12-23 | 2004-07-15 | Universität Tübingen | Method for the production of nitrate-containing precursors for metal oxides and oxocuptrate superconductors |
CN101035892A (en) * | 2004-10-04 | 2007-09-12 | 诺维信公司 | Polypeptides having phytase activity and polynucleotides encoding same |
WO2007112739A1 (en) * | 2006-04-04 | 2007-10-11 | Novozymes A/S | Phytase variants |
CN101756069A (en) * | 2009-12-16 | 2010-06-30 | 湖南农业大学 | High-efficiency and environment-friendly feed additive for pigs and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11172693B2 (en) | Feed additive composition | |
US11235035B2 (en) | Feed additive composition | |
US20200276279A1 (en) | Feed additive composition | |
CA3004522C (en) | Feed additive composition | |
US20190076488A1 (en) | Feed additive composition | |
CN104684408B (en) | Feed addictive composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |